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Analgesics are commonly used drugs but we are lacking knowledge of trends, persistence, 
high-risk use and the association with pain sensitivity at a population-level. 
Purpose 
To describe the use of analgesics, particularly persistent analgesic use, in a general population 
(30+ years), including change over time, contraindications and drug interactions, risk factors, 
and associations with pain sensitivity. 
Methods 
The Tromsø Study, including Tromsø 5 (2001-02, n = 8,030) and Tromsø 6 (2007-08,  
n = 12, 981), with the latter further linked with the Norwegian Prescription Database (2004-
13). 
Main results 
The age-adjusted prevalence of analgesic use increased from 53.7% to 59.6% in women and 
from 29.1% to 36.7% in men between 2001 and 2008, due to an increase in the use of non-
prescription analgesics. Several areas of potential high-risk use of analgesics were identified. 
The prevalence of persistent prescription analgesic use was 4.3% in general and 10.2% among 
those reporting chronic pain, while the incidence rate was 21.2 per 1,000 person-years; risk 
factors were chronic pain, increasing age, female sex, lower education level and most likely 
lower levels of physical activity. Analgesic use was associated with increased pain sensitivity; 
regular opioid users were more pain sensitive than regular users of non-opioid analgesics. 
Increased pain sensitivity was a risk factor for future persistent analgesic in the crude analysis. 
Conclusions 
The use of analgesics increased from 2001 to 2008. The extent of use of non-steroidal anti-
inflammatory drugs in the presence of chronic kidney disease, gastrointestinal ulcers, 
cardiovascular disease and interacting drugs increasing the bleeding risk was a particular 
cause for concern. The prevalence of persistent analgesic use was relatively low, also among 
those reporting chronic pain, perhaps indicative of limited effectiveness. Analgesic use is 
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1.1 WHAT THIS DISSERTATION IS ABOUT 
This dissertation is about the use of analgesics, i.e. painkillers, in the general adult (30+ years) 
population. The purpose is to describe how and why analgesics are used, with a special focus 
on long-term or persistent use. The dissertation consists of three papers, all using data from 
the Tromsø Study, conducted in Tromsø, Norway. In the first paper we present a general 
overview of analgesic use, including both non-prescription (OTC) analgesics and prescription 
(Rx) analgesics. It provides data on the change in use between 2001-02 and 2007-08, in 
addition to prevalence of use in high-risk groups, i.e., in the presence of contraindications or 
potential drug interactions. In the second paper, we narrow the focus to persistent analgesic 
use. We link the Tromsø Study to the Norwegian Prescription Database (NorPD) and develop 
a definition of persistent analgesic use. We use this definition to estimate the prevalence, 
incidence rate and the association with risk factors, particularly chronic pain and different 
aspects of chronic pain. In the third and final paper, using the definitions developed in the first 
two papers, we focus on a particular potential risk factor for analgesic use: increased pain 
sensitivity. Increased pain sensitivity may both be a risk factor for analgesic use and a 
consequence of analgesic use. We try to address if pain sensitivity can explain analgesic use, 
in relation to pain mechanisms and the effectiveness of analgesics. 
1.2 HISTORY OF ANALGESIC USE 
People have used painkillers, e.g., in the form of extracts, dry leaves/bark, in traditional 
medicine for centuries. Most of the analgesics that are in use today are natural occurring 
substances or synthetic substances based on the chemical structure and/or the pharmacological 
properties of the original natural compounds. Myrtle leaves have been used for rheumatic and 
back pain as far back as 1500 BC, while at the time of Hippocrates (400 BC) people were 
recommended to chew bark from the willow tree to treat fever or pain.1,2 Likewise, extracts 
from the opium poppy have been used as analgesics for thousands of years.3(p515) Different 
plants from the genera Salix, including the willow tree, and Spiraea have been used to remedy 
fever, inflammation and pain.2 In Norway, including the northern parts of the country, the 
willow tree is widely abundant, giving reason to believe that the analgesic properties where 
known also in this part of the world. Willow bark contains salicin which is metabolized in 
vivo into salicylic acid.2 After the discovery of salicin, salicylic acid became the chemical 
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precursor of acetylsalisylic acid (ASA), known as aspirin (“Acetyl Spiraea”) – a drug still in 
use today.1 ASA later lead to the discovery and development of the widely used non-steroidal 
anti-inflammatory drugs (NSAIDs), with ibuprofen being marketed in 1969.1 
Another plant of immense importance is Papaver somniferum (literally: poppy bringing sleep) 
– the opium poppy. Natural compounds originating from the opium poppy have been known 
since ancient times to give effects like euphoria, analgesia, sleep (hence the name of the 
poppy) and to stop diarrhea.3(p515) The chemical structure of the archetypical opioid, morphine 
(named after the Greek god of sleep, Morpheus), was determined in 1902, leading to the 
development of a range of synthetic and semi-synthetic opioids.3(p515)   
In an attempt to find a remedy against worms, the antipyretic effects of acetanilide (later 
called “antifebrin”) was discovered by serendipity in 1884.4 This led to the synthesis of 
phenacetin. Phenacetin, ASA, and, additionally, phenazone, became the first fully synthetic 
analgesics – and early “block-busters”.4 Due to limiting side effects of phenacetin, an active 
metabolite of phenacetin named paracetamol (or acetaminophen in the USA) was developed. 
Paracetamol was marketed and supplanted phenacetin in the 1950s.4 
1.3 DEFINITION OF ANALGESICS 
1.3.1 Analgesics 
Analgesics (painkillers, pain relievers) are, according to the Medical Subject Heading, defined 
as “compounds capable of relieving pain without the loss of consciousness”.5 The word 
analgesic comes from analgesia, literally meaning “painlessness” (from Greek an- “not” + 
algein “feel pain”).6 The analgesics may also possess antipyretic, i.e., fever-reducing, or anti-
inflammatory (historically called antiphlogistic) actions. 
In this dissertation, classical analgesics are defined as NSAIDs, opioids or drugs belonging to 
the Anatomical Therapeutic Chemical classification system (ATC, whocc.no)7 group N02B 
(“other analgesics and antipyretics”), including paracetamol, ASA and phenazone-caffeine. 
Drugs used in pain management but with other primary indications, e.g., antiepileptics and 
antidepressants, are often termed atypical or adjuvant analgesics or co-analgesics.  
1.3.2 Non-steroidal anti-inflammatory drugs 
NSAIDs are drugs that inhibit the cyclo-oxygenase (COX) enzyme, producing anti-
inflammatory, anti-pyretic and analgesic effects.3(p320) The chemical structures are not based 
upon the steroid structure, hence the name “non-steroidal”. ASA may be considered as the 
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mother-NSAID, but is often kept separate from other NSAIDs due to its slight difference in 
pharmacology and dual indication, i.e., use as an anticoagulant and cardio-protective agent. 
Sometimes the term “non-aspirin NSAID” (NANSAID) is used to make a distinction between 
ASA and other NSAIDs.8 The COX-2 inhibitors, or “coxibs” belong among the NSAIDs but 
are sometimes kept distinct from other (“traditional”) NSAIDs in the literature.3(p317) 
Glucosamine was approved as a drug in Europe in 2003 and included in the same ATC group 
as the NSAIDs, M01A. However, according to a widely cited systematic review from 2010, 
glucosamine is ineffective in reducing joint pain in osteoarthritis of the knee or hip.9 
Furthermore, a prescription registry study shows that use of glucosamine do not reduce the 
use of analgesics, which provides indirect evidence of lack of clinical effect.10 Glucosamine is 
therefore, and due to the different pharmacodynamic properties, often excluded in studies on 
NSAIDs.11-13 In this dissertation, NSAIDs are defined as all drugs in the ATC group M01A, 
which includes both “traditional” NSAIDs and COX-2 inhibitors but not ASA, excluding 
glucosamine. The topical NSAIDs in M02A were thus not included. 
1.3.3 Other analgesics and antipyretics 
The ATC group N02B, “other analgesics and antipyretics”, includes paracetamol, ASA and 
phenazone-caffeine in Norway (the cannabinoid Sativex® has recently been marketed). The 
use in this group is highly dominated by paracetamol. Paracetamol is an analgesic with 
antipyretic effect but weak anti-inflammatory action. Paracetamol is sometimes classified as 
an NSAID, like in a reference book in pharmacology,3(p324) but is commonly not regarded as 
an NSAID due to the lack of anti-inflammatory effect and a different adverse effects profile. 
“Other analgesics and antipyretics” are defined as all drugs belonging to the ATC group 
N02B. Unless otherwise stated, we define paracetamol as belonging to ATC group N02B, 
while paracetamol-codeine is classified as an opioid (N02A).  
1.3.4 Opioids 
Opioids are defined as “any substance, whether endogenous or synthetic, that produces 
morphine-like effects that are blocked by antagonists such as naloxone”.3(p517) The term 
“opiates” actually means natural occurring substances from the opium poppy, and therefore 
includes, among others, morphine and the cough suppressant noscapine, with the latter having 
no analgesic action. Furthermore, an opioid may be fully synthetic and not naturally 
occurring, e.g., pethidine. However, the term “opiates” is sometimes used interchangeably 
with “opioids” in the literature. In this dissertation, opioids are defined as any drug belonging 
to the ATC group N02A. Codeine alone (R05DA04) is not included, due to its main use as a 
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cough suppressant and low use in general.14 Opioids mainly used in the treatment of opioid-
addiction (N07BC) are also not included. 
1.4 PAIN 
1.4.1 Definition of pain 
The word “pain” stems from the Latin word poena meaning “penalty”, cf.  “penal code” or 
“penal institution”.6 The International Association for the Study of Pain (IASP) defines pain 
as: 
“An unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage.”15 
This definition does not connect pain exclusively to tissue damage or a pathophysiological 
cause, as pain is a subjective experience that may also occur in the absence of such 
damage.3(p509),15 Pain is thus not only related to the physiological transduction of a noxious 
stimulus but also has a strong emotional (affective) component as well as involvement of 
cognitive processes in the brain.3(p509),16 
Pain is a biological warning sign but when it chronifies and “outlives its usefulness as a 
warning system” pain becomes a debilitating disease in its own right.16,17 Chronic pain has 
been defined as pain persisting beyond the normal time of healing.18 However, IASP has 
allowed for flexibility in the definition of chronic pain, both in respect of the duration, e.g., 
one month, three months, six months, or conditions where “healing” has not occurred, e.g., 
rheumatoid arthritis, or recurring pain, e.g., migraine. Chronic pain has also been suggested to 
be “a persistent pain that is not amenable, as a rule, ( … ) to the routine methods of pain 
control such as nonnarcotic analgesics”.18  
1.4.2 Pain mechanisms 
Nociception refers to the “the neural process of encoding noxious stimuli”,15 and includes the 
molecular mechanisms by which primary sensory neurons detect these stimuli.16 The concept 
of nociception is important for the understanding of pain but pain does not equal 
nociception.3(p509) Briefly and simplified, a noxious stimulus, either mechanical, chemical or 
thermal, activates nociceptors, i.e., nerve endings of nociceptive afferent neurons projecting 
from the dorsal horn of the spinal cord, with further transmission of the signal to the brain 
(Figure 1). Nociceptive afferent neurons are broadly classified into fast conducting, partly 
myelinated Aδ-fibers, where activation produces a sharp, well-localized “first pain”, while the 
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second class consists of slow-conducting, unmyelinated C-fibers, which gives rise to a dull, 
diffuse and burning “second pain” upon activation.3(p509),16 Tissue injury also results in 
inflammation and a release of a range of chemicals (“the inflammatory soup”) from 
neighboring cells, which either activate the nerve terminals directly or enhance the sensitivity 
of the nociceptor.3(p509),16 Sensitization of peripheral nerve terminals, i.e., lowering of the 
activation thresholds, is mediated by, among others, prostaglandins and bradykinin.3(p510),16 
The nociceptive afferent neurons also contain neuropeptides, particularly substance P and 
calcitonin gene-related peptide, which facilitates the production of the inflammatory soup 
causing neurogenic inflammation.3(p509),16 In addition to peripheral sensitization, central 
sensitization occurs when there is an “increased responsiveness of spinal cord “pain” 
transmission neurons”, where activation of non-nociceptive primary sensory fibers also 
produces pain.16 Peripheral sensitization in addition to central facilitation of the transmission 
in the dorsal horn, i.e., “wind-up”, where repeated stimuli lead to an increasing amplitude of 
synaptic potentials, can produce the clinical condition hyperalgesia. 3(p510) Hyperalgesia is 
present when a stimulus that normally causes pain, produces increased pain.15 The brain 
controls the impulse transmission in the dorsal horn through a process termed descending 
inhibitory control. Inputs from many parts of the brain control the “nociceptive gate” in the 
dorsal horn through the periaqueductal grey of the midbrain. Important transmitters in this 





Figure 1 Nociception and mechanism of action of analgesics. A noxious stimulus 
activates nociceptors (here: C-fibers), with cell bodies located in the dorsal horn 
of the spinal cord. Injury results in inflammation with the release of several 
mediators (“the inflammatory soup”), including prostaglandins, which sensitizes 
the nociceptor or activates them directly. The signal travels from the dorsal horn 
to the brain, while the pain is inhibited through the descending inhibitory 
pathways. NSAIDs mainly inhibit the production of the pro-inflammatory 
prostaglandins peripherally but also have central action. Opioids act centrally by 
reinforcing the descending inhibitory pathways and peripherally by inhibiting the 
excitation of nociceptive nerve terminals. 5-HT: serotonin, BK: bradykinin, CGRP: 
calcitonin gene-related peptide, GABA: gamma-amino butyric acid, NA: 
noradrenaline, NGF: nerve growth factor, NO: nitric oxide, NSAID: non-steroidal 
anti-inflammatory drug, PG: prostaglandin, SP: substance P. Reproduced with 
permission from Rang et al.3 
1.4.3 Experimental pain 
The large differences in reported pain among patients with the same clinical condition, i.e., 
disease or trauma, may reflect individual differences in pain sensitivity.19 Pain sensitivity is 
not clearly defined in the literature but can only be appraised in controlled, experimental pain 
settings, e.g., by measurement of pain threshold or pain tolerance.19 Pain threshold is defined 
as “the minimum intensity of a stimulus that is perceived as painful”, while pain tolerance is 
defined as “the maximum intensity of a pain-producing stimulus that a subject is willing to 
accept in a given situation”.15 The aforementioned pain definition does not tie pain to a 
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stimulus.15 However, experimental pain models measure the psychophysical response toward 
a nociceptive stimulus, i.e., a proxy measure of pain.17 For example, the cold pressor test 
(CPT) used in this dissertation, involves submerging of the hand in cold water. This stimulus 
activates peripheral nociceptors as well as central pain systems to produce a tonic, deep, dull 
aching pain.20 
1.5 MECHANISM OF ACTION OF ANALGESICS 
1.5.1 Non-steroidal anti-inflammatory drugs 
The NSAIDs bind to the COX enzymes and inhibit the production of pro-inflammatory 
prostaglandins from arachidonic acid.16 Prostaglandins, particularly PGE2, are not by 
themselves pain evoking substances but they play a central role in inflammation and 
peripheral sensitization of the nociceptors (Figure 1).16 NSAIDs also have a central action, 
possible through central inhibition of prostaglandin release in the spinal cord.3(p321) The COX 
enzyme exists in two important isoforms, COX-1 and COX-2. The COX-1 enzyme is 
constitutively expressed in different cells and tissues, including the gastric endothelium, 
kidney and platelets, while the COX-2 enzyme is induced by inflammation.21  
1.5.2 Paracetamol 
Well over a century after its discovery, the mechanism of action of paracetamol is still largely 
unknown. Paracetamol has analgesic and antipyretic actions but no or only weak anti-
inflammatory activity.3(p324) One hypothesis, although questioned in recent years, is that 
paracetamol is an inhibitor of a third isoform of the COX enzyme, COX-3, present in the 
central nervous system (CNS),3(p324),4,21 while it may also have other effects in the CNS, on 
the COX-2 enzyme, or on transient receptor potential (Trp) channels.3(pp324,526)  
1.5.3 Opioids 
The binding of opioids (agonists) to opioid receptors, particularly μ receptors, produces 
antinociception and analgesia. Opioids also reduce the affective component of pain.3(pp518-9) 
For a long time the role of the opioid receptors in the body was not clear, as no endogenous 
ligand was found. However, later it was discovered that the body has its own opioids, the 
enkephalins, which bind the opioid receptor. The enkephalins belong to a larger family of 
endogenous opioids called endorphins.3(p517) The periaqueductal grey in the midbrain and the 
substantia gelatinosa in the dorsal horn of the spinal cord are rich in opioid receptors.3(pp510-1) 
The opioids produce their analgesic effect both at the supraspinal and spinal level, through 
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activation of the descending inhibitory pathways and inhibition of transmission through the 
dorsal horn, i.e., a “closing” of the nociceptive gate (Figure 1).3(pp511,519) Additionally, the 
opioids seem to have peripheral action by inhibiting excitation of nociceptive nerve 
terminals.3(p519) 
1.6 BENEFITS AND RISKS OF ANALGESIC USE 
1.6.1 Effectiveness and efficacy of analgesics 
The opioids have been most extensively studied and also show the most positive evidence in a 
large number of clinical or experimental pain settings, followed by the NSAIDs.17 Perhaps 
surprisingly, the NSAIDs show an equivocal evidence of efficacy in inflammatory arthritis.17 
A recent network meta-analysis concludes that diclofenac is the most effective NSAID in 
osteoarthritis, while treatment with paracetamol alone is ineffective.22 Recent systematic 
reviews show a limited or unproven effectiveness/efficacy of long-term analgesic use or use 
in chronic pain: the evidence of long-term opioid use in chronic pain is insufficient,23,24 the 
evidence of efficacy of paracetamol in chronic pain is limited,25 the effectiveness of long-term 
opioid therapy of chronic low back pain is unproven,26 while NSAIDs show only a small 
effect with low level of evidence in chronic back pain.27 This is further supported by 
epidemiological evidence showing that around two thirds of chronic pain patients using 
prescription analgesics report that their prescription analgesics are inadequate to control the 
pain,28 while around 90% of opioid users with chronic pain still report moderate, severe or 
very severe pain.29 However, Moore et al. argue that most analgesics work well but only in a 
minority of patients, and that the choice of treatment should be based on the individual’s 
response to treatment and not the reported average response in the population.30 
1.6.2 Risks of analgesic use 
The potential benefits of analgesic use must be weighed against the risks. Analgesics, and in 
particular the opioids and NSAIDs, are associated with several potential serious adverse 
effects and drug interactions. Briefly, NSAID use increases the risk of cardiovascular disease 
(CVD), including myocardial infarction and stroke, heart failure, kidney failure and 
gastrointestinal bleeding.31-35 Although the adverse effects of NSAIDs seem to be a group 
effect, individual differences between the substances exist, depending on the degree of 
selectivity of COX-1 or COX-2. Gastrointestinal adverse effects are most strongly associated 
with COX-1 selective NSAIDs, including naproxen, although all NSAIDs, including COX-2 
inhibitors, increase the risk of upper gastrointestinal complications.31 The risk of CVD is 
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particularly associated with the COX-2 inhibitors, but diclofenac is comparable in terms of 
risk, while naproxen is associated with the lowest relative risk.31,34 Regarding analgesic doses 
of NSAIDs there seems to be a plateau for the effectiveness, while the risk of adverse effects 
generally increases with dose without any ceiling effect.36 NSAIDs are furthermore associated 
with a range of drug interactions, with the most noteworthy potential pharmacodynamic 
interactions involving angiotensin converting enzyme (ACE) inhibitors/angiotensin II (AT II) 
antagonists (renal insufficiency), other antihypertensives (antagonized effect), anticoagulants 
(bleeding), and selective serotonin reuptake inhibitors (SSRIs) and oral glucocorticoids 
(bleeding).37(pp249-53),38  
Common, important adverse effects of the opioids include respiratory depression, nausea, 
vomiting and constipation. Opioid use may lead to tolerance development, physical and 
psychological dependence, as well as opioid-induced hyperalgesia (OIH; more in section 
1.14).3(pp519-23),37(pp5-6) Concurrent use of opioids with other CNS depressant drugs, e.g., 
benzodiazepines, increases the risk of accidents, e.g., falls or car accidents, sedation and 
respiratory depression.39 
Paracetamol is considered acceptable safe in recommended doses. However, among 
individuals with hepatic dysfunction therapeutic doses may lead to aggravated dysfunction 
and possible hepatic failure. Supratherapeutic doses of paracetamol are hepatotoxic and may 
cause severe liver injury.37(pp200-19) Paracetamol use is furthermore linked to possibly increased 
blood pressure and risk of CVD.37(pp200-19),40 
1.7 LITERATURE SEARCH 
The literature search was conducted mainly in PubMed, with additional searches in Embase 
and Google Scholar (final search date January 30, 2016). As the literature on analgesics is 
extensive, I have chosen to limit the following literature review mainly to 
pharmacoepidemiological studies on analgesic use in a general, predominantly adult 
population and/or with topics similar to this dissertation. This is presented in tables (Table 1-
3) or in relevant text, while selected studies published after the planning of this research 




1.8 SALES OF ANALGESICS 
The sales of analgesics has had an increasing trend over the last decades in the Nordic 
countries41-45 but also in other Western countries.46,47 Denmark has historically had the highest 
sales of the Nordic countries and is still on the top today, while Norway has been (1988) and 
still is at the bottom.41,43 Between 2002 and 2006 the sales of opioids increased in the Nordic 
countries (except Sweden),48 while opioid consumption in Denmark increased with more than 
600% from 1984 to 2002.29 While Denmark has had a decline in analgesic sales over the last 
10 years (2005-13), the sales has increased in the other Nordic countries (2005-14).43 Selected 
events that may have affected the availability and sales in Norway over the last decades is 
shown in Figure 2. 
The defined daily dose (DDD) is “the assumed average maintenance dose per day for a drug 
used for its main indication in adults”.7 The total sales of analgesics in Norway was around 
100 DDD/1,000/day in 2014.45 This suggests that, on average, approximately 10% of the 
population uses one DDD of an analgesic per day. The consumption statistics are useful for 
monitoring overall trends in drug use in the population and for comparison between countries. 
However, the consumption statistics provide a measure of drugs sold and may deviate from 
recommended dose, prescribed daily dose or actual use.7 Furthermore, the consumption 
Figure 2 Time line of important events in relationship to analgesic use in Norway. ASA: 
acetylsalicylic acid, COX-2 inhibitors: cyclooxygenase 2 inhibitors or coxibs, NSAIDs: 
non-steroidal anti-inflammatory drugs, OTC: non-prescription, Rx: prescription, 
Sources: Hawkey1, weifa.no and personal communication, Solveig Sakshaug, Norwegian 
Institute of Public Health. 
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statistics provide aggregated data and not individual data. For example, an increase in sales of 
analgesics may be due to increased prevalence, more intensive treatment, or a combination of 
both, or changes in stockpiling/amount discarded. Finally, sales statistics, not being 
individual-level data, cannot provide insight into risk factors or subgroups. 
1.9 PREVALENCE OF ANALGESIC USE 
As shown in Tables 1-3, the definition of analgesic use and the composition of the study 
population, e.g., the age- and sex-distribution, vary largely between different studies. This 
makes a direct comparison of prevalence measures between different studies challenging. 
Nevertheless, Nordic studies with comparable definitions of use and based on data from the 
end of the 80s49-51 and the mid-90s52 report a prevalence of 28-42% among women and 13-
27% among men; the prevalence of OTC use is higher than Rx use (30-37% vs. 12-13% 
among women).53,54 Paulose-Ram et al. report a prevalence of prescription analgesic use of 
9% and OTC analgesic use of 87% in the USA (data from ~1990),55, suggesting large 
differences in analgesic use between the Nordic countries and the USA. A Scottish study 
reports a prevalence of OTC analgesic use of 37% in 2002.56 
1.10 TRENDS IN ANALGESIC USE 
The number of prescription analgesic users in Denmark increased by 10% from 2002 to 
200442, the prevalence of prescription NSAID use in Denmark and Finland increased slightly 
from 1997 to the early 2000s,11,57 while the prevalence of opioid use in Norway increased by 
9% in 2004-07.58 The one-year period prevalence of prescription analgesic use (including 
glucosamine) in Norway was slightly higher in 2012 compared to 2004 (23.4% vs. 
22.9%).59(search:Mar8'16) In all, these studies on individual analgesic groups and the sales 
statistics suggest an increasing use of analgesics (at least in the Nordic countries). However, 







Table 1: Pharmacoepidemiological studies of prevalence and trends in analgesic use in the general population (cont.) 
Author #1 Year Title Definition Population Prevalence Selected findings 
Ahonen R  1991 Use of analgesics in a rural Finnish population. 
[ABSTRACT]60 
RX: Current 
OTC: Use last week 
Finnish farmers 
(n = 12,056) 
NA Risk factors: 
Pain, chronic morbidity, frequent use of 
physician service, psychoneurotic 
symptoms, female sex 
Ahonen R 1991 Consumption of analgesics and anti-
inflammatory drugs in the Nordic countries 
between 1978-1988.41 
N02/M01 (OTC/Rx) 





 Increased 15-42% 1978-88 
Lowest consumption in Norway (1988: 
61 DDD/1,000/day) 
Eggen AE  1993 The Tromso study: frequency and predicting 
factors of analgesic drug use in a free-living 
population (12-56 years).50 
OTC/Rx 
Use last two weeks 
Age 12-56 years 






Eggen AE 1994 Use of codeine analgesics in a general 
population. A Norwegian study of moderately 
strong analgesics.61 
Codeine (Rx) 
One-year period prevalence 
Age 10-99 years 




Antonov K 1996 Use of analgesics in Sweden - the importance of 
sociodemographic factors, physical fitness, 
health and health-related factors, and working 
conditions.49 
OTC/Rx 
Use last two weeks 
Age 16+ years  





Decreasing age (in multiple regression), 
female sex, lifestyle, sleeping problems, 
health care utilization 
Eggen AE 1996 The use of controlled analgesics in a general 
population (15-59 years)- the influence of age, 
gender, morbidity, lifestyle and 
sociodemographic factors.62 
Opioids (Rx) 
One-year period prevalence 
Age 15-59 years 




Poor self-reported health, headache, 
previous use of 
analgesics/psychotropics, low education 
level, daily smoking 
Furu K 1997 Legal drug use in a general population: 
Association with gender, morbidity, health care 
utilization, and lifestyle characteristics.51 
OTC/Rx 
Use last two weeks 
Age 20-59 years 





Antonov KI 1998 Prescription and nonprescription analgesic use in 
Sweden.53 
OTC/Rx 
Use last two weeks 
Age 18-84 years 
(n = 11,996) 
W, Rx: 12% 
W, OTC: 30% 
M, Rx: 7% 
M, OTC: 20% 
Risk factors: 
Headache, musculoskeletal pain, poor 
self-reported health (Rx), smoking, 
alcohol use (W), poor physical function 
(Rx) 
Furu K 2001 Validity of questions in the use of specific drug-
groups in health surveys.54 
OTC/Rx 
Use last two weeks 
Age 20-79 years 
(n = 6,702) 
W, Rx: 13% 
W, OTC: 37% 
M, Rx: 8% 
M, OTC: 20% 
30% of Rx users were daily users 
Curhan GC 2002 Frequency of use of acetaminophen, 
nonsteroidal anti-inflammatory drugs, and 
aspirin in US women.63 
Paracetamol/ASA/NSAIDs (OTC/Rx) 
Regular medication past two years 
Women, aged 33-
77 years 




42% ≤51 years 
 
Isacson D 2002 Epidemiology of analgesic use: a gender 
perspective.52 
OTC/Rx 
Use last two weeks 
Age 20-84 years 
(n = 5,404) 
W: 35% 
M: 21% 
Risk factors (of sex difference): 






Table 1: Pharmacoepidemiological studies of prevalence and trends in analgesic use in the general population (cont.) 
Author #1 Year Title Definition Population Prevalence Selected findings 
Paulose-
Ram R 
2003 Prescription and non-prescription analgesic use 
among the US adult population: results from the 
third National health and nutrition examination 
survey (NHANES III).55 
OTC/Rx 
Use last month 
Age 17+ years  
(n = 20,050) 
W, Rx: 11% 
W, OTC: 81% 
M, Rx: 7% 
M, OTC: 71% 
↑ Women 
OTC: ↓ Age 
Rx: ↑ Age 
Motola D  2004 Pattern of NSAID use in the Italian general 
population: a questionnaire-based survey.64 
NSAIDs (OTC/Rx) 
Use last week 
 
Chronic use: Daily or frequent use > 6 months 
Age 18+ years  
(n = 2,738) 
23% 




Female sex, unspecified pain, 
musculoskeletal disorder 
Chronic use: 
Cardiovascular diseases, nervous 
system disorders 
Diener HC 2005 Per-capita consumption of analgesics: a nine-
country survey over 20 years.46 
Sales in “standardized units” 
N02B 
  Generally increased 1986-2005 but 
large variations between countries 
(Sweden on top) 
Rosenzweig 
M  
2006 [The use of analgesics in Denmark, 2000-
2004].42 
Opioids/N02B/NSAIDs (OTC/Rx) Total Danish 
population 
2002-04:  
10% increase in 
Rx users 
 
Increase in RX sales, not OTC 
Fosbøl EL 2008 The pattern of use of non-steroidal anti-
inflammatory drugs (NSAIDs) from 1997 to 
2005: a nationwide study on 4.6 million 
people.11 
NSAIDs (Rx) Age 10+ years 1997-2005:  
15%  17% 
Risk factors: 
Female sex, increasing age, rheumatic 
disease, other analgesics 
Garcia del 
Pozo J 
2008 Trends in the consumption of opioid analgesics 
in Spain. Higher increases as fentanyl replaces 
morphine.47 
Opioids (reimbursed Rx) 




14-fold increase in sales  
Hamunen K 2009 Trends in opioid consumption in the Nordic 
countries 2002-2006.48 
Opioids 





 Increase, except Sweden 
Fredheim 
OM 
2010 Increasing use of opioids from 2004 to 2007 - 
pharmacoepidemiological data from a complete 
national prescription database in Norway.58 
Opioids (Rx) 




of those for cancer 
pain) 
 
4% of chronic non-cancer pain patients 
>400 DDDs/year 
2004-07: 9% increase 
Mijatovic V 2011 Consumption of non-steroidal anti-inflammatory 
drugs in Serbia: a comparison with Croatia and 
Denmark during 2005-2008.65 
NSAIDs (Rx) 
Sales in DDD/1,000/day 
 
Total populations 
of Serbia, Croatia 
and Denmark 
 Large differences between countries  
Decrease/stable 
Duong M 2014 Usage patterns of 'over-the-counter' vs. 
prescription-strength nonsteroidal anti-
inflammatory drugs in France.13 
NSAIDs 
Reimbursed dispensings (includes OTC) 
 
Age 10+ years, 
salaried workers 




OTC users younger than Rx users 
OTC users more often female than Rx 
users 
Chronic comorbidities: 
19% of OTC users 





Table 1: Pharmacoepidemiological studies of prevalence and trends in analgesic use in the general population (cont.) 
Author #1 Year Title Definition Population Prevalence Selected findings 
Neutel CI 2014 Trends in prescription of strong opioids for 41-
80 year old Norwegians, 2005-2010.66 
Only strong opioids (Rx) 
One-year period prevalence 







20% received more than one type of 
opioid annually 
DDD per prescription did not change 
substantially 
Schmidt M 2014 Potential of prescription registries to capture 
individual-level use of aspirin and other 
nonsteroidal anti-inflammatory drugs in 
Denmark: trends in utilization 1999-2012.12 
NSAIDs (OTC/Rx) 
One-year period prevalence 
Sales in DDD/1,000/day 
 




14%  15% 
2004-12:  13% 
↑ Women  
 
Use of coxibs almost ceased, while 
diclofenac use halved since 2008 
Zin CS 2014 Changes in trends and pattern of strong opioid 
prescribing in primary care.67 
Strong opioids (Rx) 
Annual number of prescriptions 
DDD/1,000/day 
Age 18-107 years 
(n = 5,404) 
2000-10: 0.18% 
 0.92%  
12% of prescriptions issued with or 
following cancer diagnosis 
Greater increase in number of 
prescriptions than users 
Dale O 2015 Prevalence of use of non-prescription analgesics 
in the Norwegian HUNT3 population: Impact of 
gender, age, exercise and prescription of 
opioids.68 
Paracetamol/NSAIDs/ASA (OTC) 
Use at least once a week in the last month 
Age 20+ years  





NSAIDs: ↓ Age 
ASA: ↑ Age 
Paracetamol: - Age 
Risk factors (daily use):  
Female sex, increasing age, low 
physical activity, headache, increasing 
pain intensity 
Frenk SM 2015 Prescription opioid analgesic use among adults: 
United States, 1999-2012.69 
Opioids (Rx) 
Past 30 days 
Age 20+ years 1999-2006: 5%  
7%, thereafter 
stable to 2012  
↑ Women  
 
Ruscitto A 2015 Changes in opioid and other analgesic use 1995-
2010: repeated cross-sectional analysis of 
dispensed prescribing for a large geographical 
population in Scotland.70 
Any analgesic use (includes topical NSAIDs and 
gabapentinoids, Rx) 
Dispensed analgesic within 84 days preceding index 
date 
Age 20+ years  
(n = 301,020 and 
n = 311,881) 
1995-2010:  
16%  18% (RR 
= 1.09) 
Paracetamol, opioids and 
gabapentinoids increased, the rest 
decreased 
18-fold increase in strong opioids 
Use of multiple analgesic classes 
increased 
Sarganas G 2015 Prevalence, trends, patterns and associations of 
analgesic use in Germany.71 
ASA/Diclofenac/Ibuprofen/Paracetamol/Naproxen 
(OTC/Rx) 
Use last 7 days 
Age 18-79 years 
(n = 7,099 and n 
= 7,091) 
1998-2011:  
19%  21% 
Increase due to OTC analgesics only: 
10%  12% 
Rx use remained constant 
Risk factors: 
Female sex, smoking, obesity with 
medium/high socioeconomic status 
(Rx), low physical activity level 







Table 2 Pharmacoepidemiological studies of persistent or regular analgesic use in the general population (cont.) 




2003 Heavy users of non-steroidal anti-inflammatory 
drugs: a nationwide prescription database study in 
Finland.57 
NSAIDs (Rx) 
Heavy use: ≥ 182 DDDs/year 
Reimbursed prescriptions only 
All ages  
(n = 500,000) 
1.5% in 2000 
1997-2000: 
Relatively stable 
(18%  19%) 
Risk factors: 




2005 Frequent monthly use of selected non-prescription 
and prescription non-narcotic analgesics among 
U.S. adults.8 
Non-opioids (OTC/Rx) 
Frequent use: Nearly every day for a 
month 
Age 20+ years 




Use ≥ 1 year: 
46% of NSAID users 
63% of paracetamol users  
Turunen JH 2005 Frequent analgesic use at population level: 
prevalence and patterns of use.72 
OTC/Rx 
Frequent use: Daily or a few times a 
week 
Age 15-74 years 
(n = 4,542) 
Rx only: 9% 
OTC only: 9% 
Both OTC & Rx: 
5% 
Risk factors: 
Increasing age (slightly), not working, lower 
education level, chronic diseases, low mood, longer 
pain duration, more severe pain, more frequent pain 
Eriksen J 2006 Critical issues on opioids in chronic non-cancer 
pain: an epidemiological29 
Opioids 
Positive response to continuous or regular 
use 
Age 20+ years 




Moderate/sever pain, poor self-reported health, 
unemployment, higher use of health care system 
Hudson TJ 2008 Epidemiology of regular prescribed opioid use: 
results from a national, population-based survey.73 
Opioids (Rx) 
Regular use: At least several times a 
week for a month or more 
Age 20+ years 
(n = 7,909) 
2% No sex difference 
Risk factors: 
Painful condition (arthritis, chronic back problems, 
migraine/chronic headache), high pain interference, 
lower health status 
Parsells 
Kelly J 
2008 Prevalence and characteristics of opioid use in the 
US adult population.74 
Opioids (Rx)  
Regular use: ≥ 5 days per week for ≥ 4 
weeks 
Age 18+ years 
(n = 19,150) 
2% Risk factors: 
Increasing age, female sex, lower education level 








≥ 90 days,  
≥ 10 prescriptions, and/or ≥ 120 days 
supply 
Age 18+ years NA ≈ 5% of treatment episodes were long-term 
episodes with a mean duration ≈ 900 days 





≥ 90 days, ≥ 10 prescriptions, and/or ≥ 
120 days supply 









2010 Factors associated with a continuous regular 
analgesic use - a population-based study of more 
than 45,000 Danish women and men 18-45 years 
of age.77 
Paracetamol/Ibuprofen/ASA (OTC/Rx) 
≥ 7 tablets per month during last year 
Age 18-45 years 




Female sex, increasing age, poor self-rated health or 
fitness, smoking, lower education  level (W), 
nulliparity (W), overweight (W), binge drinking 







Table 2 Pharmacoepidemiological studies of persistent or regular analgesic use in the general population (cont.) 
Author #1 Year Title Definition Population Prevalence Selected findings 
Svendsen K 2012 Differential patterns of opioid use: defining 
persistent opioid use in a prescription database.14 
Opioids (Rx) 
> 180 DDD or > 4,500 mg OMEQ, and at 










2013 A pharmacoepidemiological cohort study of 
subjects starting strong opioids for nonmalignant 




Dispensed a second prescription within 
70 days and dispensed an opioid in each 
year of the study period 
Total Norwegian 
population 
NA Cancer patients excluded 
Risk factors: 
Age > 60 years, past use of weak opioids 
The mean DDD increased in the study period 
Fredheim 
OM 
2014 Chronic pain and use of opioids: a population-
based pharmacoepidemiological study from the 
Norwegian Prescription Database and the Nord-
Trondelag Health Study.79 
Opioids (Rx) 
> 180 DDD or > 4500 mg OMEQ, and at 
least three quarters of the year 
Age 20+ years 
(n = 45,837) 
1% Cancer patients excluded 
Risk factors (of future persistent use): 
Occasional use, benzodiazepine use, physical 
inactivity, strong pain intensity, polypharmacy 
Svendsen K 2014 Persistent opioid use and socio-economic factors: a 
population-based study in Norway.80 
> 365 DDD or > 18,000 mg OMEQ, in 
all quarters of the year 
Age 35+ years, 
Norwegian 
population 
0.6% Cancer patients excluded 
Risk factors: 
Disability pension, divorced/separated, lower 
education level, unemployment, low income 
Zhou Y  2014 Trends in the use of aspirin and nonsteroidal anti-




≥ 3 times per week for the last 3 months 
Age 18+ years 
(n = 31,428 and 
n = 27,157) 
ASA:  
12%  19% 
NSAIDs:  
9%  13% 
↑ Women 
↑ Age (reversed U shape) 
↑ Severe headache/migraine 








Table 3: Pharmacoepidemiological studies of high-risk analgesic use in the general population (cont.)
Author #1 Year Title Definition Population Prevalence Selected findings
Sihvo  2000 Frequency of daily over-the-counter drug use and 
potential clinically significant over-the-counter-
prescription drug interactions in the Finnish adult 
population.82 
OTC 
Continuous (daily or almost 
daily) or temporary use last two 
days 
Age 16+ years (n = 10,477) Analgesics: 
4% 
NSAIDs: 4% 
Interactions (with beta-blockers, 






2005 Frequent prescribing of drugs with potential 
gastrointestinal toxicity among continuous users of non-
steroidal anti-inflammatory drugs.83 
NSAIDs (Rx) 
Continuous use: ≥ 182 
DDDs/year 
Nested case-control study in a 
systematic sample of the Finnish 
population (n = 7,652 cases) 
NA 14.5% concurrent use (increased 
bleeding risk) 
Odds ratio (OR) drugs increasing GI 
bleeding risk: 5.2 (ref. non-continuous 
use)  
Porteous T 2005 How and why are non-prescription analgesics used in 
Scotland?56 
OTC 
Use last two weeks 
General use 
Age 18+ years (n = 1,501) 37% 
 
Possible inappropriate use: 21% of 
users 
Contraindications (diseases): 9% 
Drug-drug interactions: 3% 
Risk factors: 
Decreasing age. female sex, higher 
education 
Wilcox CM 2005 Patterns of use and public perception of over-the-counter 
pain relievers: focus on nonsteroidal anti-inflammatory 
drugs.84 
NSAIDs (OTC/Rx) 
At least 2 x 5 days use last 12 
months 
Age 18+ years (n = 9,062) 17% 54% of NSAID users unaware of side 
effects 
26 % of OTC only users exceeded the 
recommended dose 
8 % of Rx users exceeded the 
prescribed dose 
Silvani MC 2006 Gastro-intestinal problems and concomitant medication in 
NSAID users: additional findings from a questionnaire-
based survey in Italy.85 
NSAIDs (OTC/Rx) 
Use last week 
 
Chronic use: Daily or frequent 
use > 6 months  
Age 18+ years (n = 2,738) 23% NSAID use among those reporting 
dyspepsia/ulcer: 
24% occasional, 6% chronic 
Use of more than one NSAID: 16% of 
users 
Glucocorticoids/SSRI: ≈18% NSAID 
use 
Anticoagulants: ≈6% NSAID use 
Adams R 2011 Cause for concern in the use of non-steroidal anti-









Chronic kidney disease: 16% 
CVD: 20% 
ACE-inhibitors: 12% 
Stosic R 2011 Responsible self-medication: perceived risks and benefits 
of over-the-counter analgesic use.87 
Paracetamol/NSAIDs (OTC) 
Once or more per month (regular 
use) 
Age 18+ years (n = 1,901 and n = 
2,209) 
2001-09:  
67%  55% 
 
Once a year: 
85% 
2009: 
96% used paracetamol appropriately 
69% used NSAIDs appropriately 
3% used more than max. ibuprofen 






Table 3: Pharmacoepidemiological studies of high-risk analgesic use in the general population (cont.)
Author #1 Year Title Definition Population Prevalence Selected findings
Boudreau 
DM 
2013 A survey of adult awareness and use of medicine 
containing acetaminophen.88 
Paracetamol (OTC/Rx) 
Use last two weeks 
Age 21-79 (n = 360, general 
population) 
36% 1.1% of the general population exceed 
4 g/day 





2014 High-risk use of over-the-counter non-steroidal anti-
inflammatory drugs: a population-based cross-sectional 
study.89 
NSAIDs (OTC) 
Use last four weeks 
Age 18+ years (n = 118, general 






Dosage exceeding maximum:  
Among 9% of users in the general 
population and 3% among high-risk 
users 
At least 10% NSAID use in the high-
risk groups examined 








1.11 PERSISTENT ANALGESIC USE 
Although much is known about the use of analgesics in general, less attention has been given 
to long-term or persistent analgesic use. Table 2 summaries studies on persistent, high-
intensity or regular use of analgesics. Most of the studies have focused on opioid use,14,73-76 
while a few studies have focused on frequent use in general or frequent use of non-opioid 
analgesics.8,72,77 The majority of studies is based on self-reported data,8,72-74,77 while a few 
utilize prescription databases.14,57,75,76 The definitions of regular/frequent or persistent 
analgesic use varies widely and makes comparison of prevalence measures difficult. In the 
USA, the prevalence of self-reported opioid use during the last month is around 2%,73,74 while 
the one-year period prevalence of persistent opioid use is 4-5%.75 A Norwegian study based 
on the total population reports a point prevalence of persistent opioid use of 1.1%, in the 
widest definition.14 In Finland, the one-year period prevalence of heavy NSAID use (≥ 182 
DDD/year) is reported to be 1.5%.57 Finally, two studies report a prevalence of self-reported 
regular use of non-opioids ~20%8,77, with the Danish study reporting a prevalence of 27% 
among women and 18% among men.77 To our knowledge no study utilizes prescription 
databases to study persistent analgesic use in general, i.e., including all the major analgesic 
groups (NSAIDs, opioids and paracetamol). 
1.12 HIGH-RISK USE OF ANALGESICS 
Studies on high-risk use of analgesics, i.e., use in the presence of contraindications, potential 
drug interactions, or high risk of adverse effects in the general adult population are 
summarized in Table 3. The majority of the studies focus on NSAID use and OTC analgesics. 
Porteous et al. report possible inappropriate use among 21% of OTC analgesic users in 
Scotland.56 In a study by Wilcox et al., more than half of NSAID users were unaware of 
adverse effects, while one quarter of users of OTC NSAIDs only used more than the 
recommended dose.84 Silvani et al. report that almost one third of those reporting 
dyspepsia/heartburn or gastrointestinal (GI) ulcer report NSAID use, 16% of users use more 
than one NSAID, and that NSAIDs are frequently used concomitantly with potential 
interacting drugs.85 Adams et al. report that 69% of NSAID users had one or more 
contraindications, e.g., CVD, chronic kidney disease (CKD), hypertension.86 An Australian 
study found a decrease in appropriate use, i.e., use in the absence of contraindications or drug 





1.13 RISK FACTORS FOR ANALGESIC USE 
In this dissertation I define «risk factor» as a «characteristic associated with an increased 
probability of occurrence of an event or disease», without necessarily implying a causal 
relationship.90 However, there is some ambiguity about this term in the literature. Porta 
defines a risk factor as being causally related to the outcome, a «risk marker» as a factor with 
a non-causal association, and “risk indicator” as a common term for both.91 “Predictor” is 
often used in the same meaning as I use risk factor in this dissertation but I prefer to reserve 
predictor as a statistical term or for actual prediction studies. A whole range of risk factors for 
analgesic use has been reported in the literature. Here I only refer what seems to be the most 
important factors.  
Pain is the obvious risk factor for analgesic use.29,50,52,53,62,64,72,73,92 The measures of pain used 
in the studies on analgesic use vary largely and are mainly based on simple, self-reported, 
dichotomous measures. However, some studies have included measures of pain 
severity.29,52,72,73,92 More intense pain, as recorded by the general practitioner (GP), increases 
the likelihood of being prescribed a stronger analgesic, although the GP’s prescribing seems 
to be more influenced by the patient’s previous use of analgesics than the pain intensity.93 
None of the aforementioned studies utilized experimental pain tests as a measure of pain. 
Furthermore, as Antonov and Isacson point out, there may be factors other than pain 
explaining analgesic use.49 Some of these factors are only important via pain, while others 
may exert an effect independent of pain. 
Female sex is one of the most commonly reported risk factors for analgesic use, with studies 
based on both self-report and prescription databases showing a higher use among 
women.11,14,49-53,55-57,61,62,64,74,77,92 In contrast, a few studies on regular/frequent analgesic use 
report no sex difference.8,72,73 
Age is a risk factor for analgesic use, although large variations exist between different studies. 
The reported age trends seems to be mostly influenced by the prescription status, i.e., OTC, 
Rx or total use, frequency of use and analgesic type in question. Studies on analgesic use in 
general have shown conflicting age trends in the prevalence of use, with either a positive 
trend49 or no or negative trend with increasing age.50-52 Several studies report that OTC 
analgesic use decreases with age,53,55,56,87 while an inverse trend is observed for Rx 
analgesics.53,55 Frequent or regular use of OTC or Rx analgesics increases with age.8,72,77 





commonly used in all ages,11 and increases with age in those without rheumatoid arthritis.57 
Opioid use increases with age.61,62,74  
Other commonly risk factors for analgesic use include poor self-reported health,29,49,53,56,62,73,77 
and lower levels of education62,72,74,77 Higher analgesic use among those with highest 
education has also been reported,50,52 possibly explained by a relatively higher use of OTC 
analgesics among those with highest education.56 Furthermore, analgesic use has been 
reported to be associated with poor mental health,50,62,72 low levels of physical 
activity/fitness,29,50,77 alcohol use and smoking,50,62,77 and factors relating to work status, e.g., 
unemployment or disability pension.29,72 
1.14 PAIN SENSITIVITY AND ANALGESIC USE 
In 2005, Edwards proposed the hypothesis that “individual differences in pain sensitivity and 
pain  inhibition, which reflect natural variability in CNS pain processing, place individuals at 
reduced or elevated risk for the development of chronic pain ( … )”.94 He suggested that the 
most pain sensitive individuals have a reduced endogenous pain inhibition and a greater risk 
of developing chronic pain, and that increased basal or inherent pain sensitivity may be a 
diathesis of chronic pain. Most chronic pain conditions are associated with dysfunctionality in 
the normal physiological pain processes.3(p510) The potential causal pathways between pain 
sensitivity and chronic pain are, however, not clear. On the one hand, increased pain 
sensitivity may be a consequence of chronic pain.95 On the other hand, increased pain 
sensitivity may put people at risk of clinical pain.19 Severe or untreated acute pain is a 
potential risk factor for development of chronic pain, possibly through sensitization of the 
CNS.94 Highly pain sensitive subjects may experience more severe acute pain, with a 
consequently higher risk of chronic pain.94 As an increased risk of pain would intuitively 
confer an increased risk of analgesic use, this suggests that highly pain sensitive subjects are 
more likely to use analgesics, i.e., increased pain sensitivity is a risk factor for analgesic use. 
However, it has been suggested that the efficacy of analgesics is reduced in highly pain 
sensitive subjects.94 If this is true, increased pain sensitivity, as a marker of hampered 
endogenous pain inhibition, not only increases the risk of chronic pain but also reduces the 
efficacy of analgesics. As previously shown, the effectiveness or efficacy of classical 
analgesics in chronic pain seems limited. Analgesics exert their effect by “recruiting 
endogenous pain-inhibitory systems” (Figure 1),94 the same systems that may be 





central sensitization and more centralized pain phenotypes.96 This could suggest that the 
highly pain sensitive subjects represent a sub group with more centralized pain phenotypes, 
e.g., fibromyalgia, a sub group that responds poorly to classical analgesics.  
To further add complexity to this matter, analgesic use may lead to a paradoxical increase in 
pain. Chronic opioid use may cause opioid-induced hyperalgesia (OIH), a state of increased 
pain sensitivity due to opioid use.97-99 Common features of OIH include a generalized, ill-
defined and diffuse pain, not necessarily located at the source of damage or disease,97 an 
increase in pain intensity over time, widespread pain and increased pain sensitivity toward 
external stimuli.99 
Several studies have been conducted on the association of preoperative pain sensitivity and 
postoperative pain, with some of the studies using analgesic use within the first days after 
surgery as a proxy measure of pain.100 The results on analgesic use have been conflicting. 
Some studies found that suprathreshold heat pain was positively correlated with the amount of 
postoperative analgesic use, while other studies found a negative correlation between heat 
pain threshold or pressure pain tolerance and postoperative analgesic use. The low sample 
sizes, highly selected study populations and the focus on pain after surgery makes it hard to 
generalize these results into more general analgesic use in the general population.  
In summary, there is a knowledge gap of the association between pain sensitivity, chronic 
pain and the use of analgesics. As far as we know, no studies on the association between pain 







2 PURPOSE AND AIMS 
The purpose of this dissertation was to study the use of analgesics in a general population, 
including risk factors for use and characteristics of the users. This included the study of 
prevalence and frequency of use, change in use over time, use in the presence of 
contraindications and drug interactions, prevalence, incidence rate and risk factors for 
persistent use, and the importance of pain sensitivity for the use of analgesics. 
The specific research questions were: 
Paper I: 
 What is the prevalence of self-reported analgesic use in the population and the change 
in use over time? 
 What is the prevalence of regular analgesic use among subjects with contraindications 
or potential drug interactions?  
Paper II: 
 What is the prevalence and incidence rate of persistent analgesic use and what are the 
risk factors? 
 What is the association between chronic pain, including different dimensions of 
chronic pain severity, and persistent analgesic use? 
Paper III: 
 Does pain sensitivity influence the use of analgesics? 
 Adjusting for other factors, do more pain sensitive subjects use more analgesics than 
less pain sensitive subjects? 






3 MATERIALS AND METHODS 
3.1 DATA SOURCES 
3.1.1 The Tromsø Study 
The Tromsø Study is an epidemiological, population-based study covering a broad range of 
health problems and diseases. So far, six waves, referred to as Tromsø 1-6, have been carried 
out between 1974 and 2008. The participants consist of inhabitants from the municipality of 
Tromsø, Norway.101,102 The Tromsø Study has been extensively described in cohort 
profiles101,102 and on the Tromsø Study home page, www.tromsostudy.com. This dissertation 
includes participants from Tromsø 5 (2001-02) and Tromsø 6 (2007-08). English translations 
of the full questionnaires are available from the home page, and relevant pages are included in 
the Appendix. 
In Tromsø 5, carried out in 2001-02, participants from the second visit in Tromsø 4 (1994-95) 
were re-invited. Very briefly, those invited to the second visit of Tromsø 4 consisted of  all 
men aged 55-74 years and women aged 50-74 years plus smaller random samples of the other 
age groups < 85 years.102 Additionally, the eligible population in Tromsø 5 was extended with 
1,916 subjects aged 30, 40, 45, 60 or 75 years. The attendance rate was higher in the group 
who had participated in Tromsø 4 (89 percent) compared to the rest (57 percent).102 In total, 
8,130 men and women aged 30-89 years attended Tromsø 5, with an attendance rate of 79% 
percent. Due to withdrawn consents, the available sample size was n = 8,039. 
Tromsø 6 was conducted in 2007-08. Invited subjects included all inhabitants aged 40-42 
years and 60-87 years (n = 12,578), a 10 % random sample aged 30-39 years (n = 1,056), a 
40% random sample aged 43-59 years (n = 5787). Once more, participants of the second visit 
to Tromsø 4 were invited, if they were not already included in the groups mentioned above (n 
= 341).101 In, total 12,984 men and women aged 30-87 years attended (66% attendance rate). 
Due to withdrawn consents, the available sample size was n = 12,981.  
The participants of Tromsø 5 and 6 received a questionnaire (Q1) with the invitation around 
two weeks before they attended. At attendance, they were delivered a second questionnaire 






The participants of Tromsø 6 underwent a health screening, including physical examinations, 
blood samples and measurement of pain sensitivity.101 Furthermore, a subgroup were invited 
to a more extensive second examination, including morning urine samples. Those invited 
included first-visit participants aged 50-62 years or 75-84 years, a 20% random sample of 
those aged 63-74 years, and participants of the second visit in Tromsø 4 (< 75 years), if not 
already included.102 The second visit occurred about four weeks after the first visit,101 and this 
sub group (n = 7,307) was older than the total Tromsø 6 sample. 
3.1.2 The Norwegian Prescription Database 
The NorPD, established January 1, 2004, is a national registry of all prescriptions dispensed to 
individual patients from Norwegian pharmacies.103 NorPD does not capture drugs dispensed 
in hospitals, nursing homes, or directly from the physician, or OTC drugs. Recorded 
information of relevance to the current project include the encrypted person-identifier (used 
for record linkage), number of packages dispensed, package size, administration form (tablets, 
capsules etc.), ATC code, number of dispensed DDDs, category of prescription, 
reimbursement codes and date of dispensing.103 
3.2 CENTRAL VARIABLES 
In the following section is a description of the analgesic use measures, i.e., outcome of 
interest, and a description of other variables used. This is, however, limited to central 
variables and/or where a more thorough explanation is called for. Other variables not 
presented here are defined and described in the respective papers. 
3.2.1 Outcome variables: Analgesic use 
Self-reported use of non-prescription and prescription analgesics (Paper I-III) 
Self-reported use of OTC or Rx analgesics were measured by the questions: “How often have 
you during the last four weeks used the following medicines? Painkillers on prescription. 
Painkillers non-prescription”, with the options not used/less than every week/every week, but 
not daily/daily. These questions were identical in Tromsø 5 and Tromsø 6. The variables were 
recoded to dichotomous measures of use (no/yes) last four weeks. Furthermore, we created 
mutually exclusive variables divided into those reporting no use, OTC analgesics only, Rx 
analgesics only and both OTC and Rx analgesics. Individuals with missing on either questions 





prescription categories, and in total (Paper I). In Paper II, we used a measure of daily/weekly 
OTC use, employing the original frequency variable. 
Self-reported regular use of analgesics (Paper I & II) 
In addition to the frequency question, participants in Tromsø 6 were asked to list all drugs, 
both OTC and Rx, used regularly the last four weeks. The drugs listed were coded according 
to the ATC-DDD 2007 version. Analgesics were defined as either NSAIDs, opioids or other 
analgesics and antipyretics (see section 1.3). Unfortunately, we were not able to compare this 
variable with the Tromsø 5 data due to differences in the questions used. In the context of 
high-risk use (Paper I), “paracetamol” includes the ATC codes N02BE01 and N02AA59 
(paracetamol + codeine), the latter is otherwise classified as an opioid. 
Self-reported analgesic use last 24 hours (Paper III) 
At attendance, participants were interviewed about their use of analgesics the last 24 hours. 
Analgesic use last 24 hours was defined as a positive response to this question, regardless of 
the type of analgesic. 
Persistent analgesic use (Paper II & III) 
No universal definition of persistent analgesic use exists but we based our definition on an 
adaptation of previously published methods.75,104,105. Using the prescription registry data, we 
defined treatment episodes of analgesic use (Figure 3).75 Consecutive analgesic prescriptions 
were said to belong to the same treatment episode if the time gap between the prescriptions 
was ≤ 180 days. Consequently, a treatment episode started if there were no analgesic 
prescriptions within the preceding 180 days and an analgesic prescription within the following 
180 days. The prescription with no subsequent prescriptions in the following 180 days was 
defined as the last prescription of the treatment episode. If several prescriptions were 
dispensed on the same date they were collapsed into one, i.e., the DDDs were summed. The 
average daily dose was calculated as the cumulative number of DDDs dispensed from the first 
prescription to the second to last prescription, divided by the number of days between the first 
and last prescription.104 The duration of the last prescription within a treatment episode was 
estimated as the number of DDDs dispensed divided by the average daily dose. The duration 
of the last prescription was limited to maximum 180 days. The duration of a treatment episode 
was the number of days between the first and last prescription plus the estimated duration of 





period. To decide if a treatment episode with analgesics was a persistent treatment episode, 
we used proportion-of-days-covered (PDC) and the duration of the treatment episode. The 
PDC is a measure of the proportion of days within a time interval with an available supply of 
drugs,106 or more specific to this context: the proportion of days within a treatment episode 
with one DDD of analgesics available. PDC was calculated as the cumulative number of 
DDDs within a treatment episode divided by the treatment duration of the episode.105 We 
defined persistent treatment episodes as those with a duration ≥ 90 days and PDC ≥ 40%. We 
chose 90 days as a reflection of the Norwegian reimbursement system for drugs, in addition to 
the definition of chronic pain, i.e., pain with duration of three months or more. A bit 
simplified, reimbursement is given when the need for treatment amounts to at least three 
months per calendar year. Finally, we conducted a range of sensitivity analyses of the 
different dimensions used in the definition, i.e., gap between prescriptions, treatment duration 







Figure 3 Definition of treatment episodes with analgesics and persistent analgesic 
use. The top part shows the treatment episodes in the study period, i.e., three 
years before to five years after attendance, illustrated as grey horizontal lines. 
An individual could have several treatment episodes. The zoomed in part shows 
the definition of treatment episodes: Vertical bars represent the date when 
prescriptions are dispensed. The treatment episode is illustrated by the grey 
area. Proportion-of-days-covered is calculated as the sum of defined daily doses 
(DDD) dispensed within a treatment episode divided by the duration of that 
treatment episode. Prevalent users: a persistent treatment episode includes the 
attendance date. Incident users: no persistent use in the three years before and 
including the attendance date, and the first persistent episode within the 4.5 







3.2.2 Exposure variables/independent variables 
Cardiovascular disease (Paper I) 
Cardiovascular disease wad defined as a positive response on either of the questions on 
myocardial infarction, stroke or angina pectoris (“Do you have or have you had …”). Persons 
with missing on either of the questions were excluded. This group was defined as the 
secondary CVD risk group. 
In an attempt to estimate the cardiovascular risk among those with no history of CVD, i.e., 
primary CVD risk, we used the NORRISK risk score, i.e., the Norwegian adaptation of the 
Systematic Coronary Risk Evaluation (SCORE) risk score.107 The NORRISK score estimates 
the ten-year risk of fatal CVD, using sex, age, systolic blood pressure, total cholesterol and 
smoking, among persons aged 40-69 years. The calculated NORRISK score produced results 
that were similar to a previous report.108 We restricted this analysis to those with no history of 
CVD (total n = 9,000), as defined above, i.e., this variable represents a sub group of subjects 
with no history of CVD, which was further stratified into subjects with or without high CVD 
risk. We used age stratified cut-offs for the NORRISK score to define high risk, as defined in 
a national guideline: 40–49 years: > 1%, 50–59 years: ≥ 5%, and 60–69 years: ≥ 10%.109 We 
also considered using Framingham heart risk score86 or SCORE.107 However, we deemed the 
NORRISK score to be the most valid measure for our study population. NORRISK is also 
included in a national guideline distributed to physicians and is also available as an online risk 
calculator.109 
Chronic kidney disease (Paper I) 
Estimated glomerular filtration rate (eGFR) was estimated by the Chronic Kidney Disease 
Epidemiology collaboration (CKD-EPI) formula using serum creatinine, sex, age and 
ethnicity (assuming 100% “white or other”).110 Serum creatinine was available for n = 12,827 
subjects. However, to produce a more valid measure of CKD, we also included data on 
albuminuria. Morning urine samples, including measurements of albuminuria, were collected 
in three consecutive days (n = 7,218) among those who attended the second visit.101 Persistent 
microalbuminuria and albuminuria were defined as previously described.111 CKD was defined 
as eGFR < 60 ml/min per 1.73 m2 or ≥ 60 ml/min per 1.73 m2 and either macroalbuminuria or 
persistent microalbuminuria. Due to missing in the variables, the final sample was n = 6,834. 
The results on CKD were generally consistent with a previous report from a similar 





Gastrointestinal ulcer (Paper I) 
Gastrointestinal ulcer was defined as a positive response to either of the questions on stomach 
ulcer, duodenal ulcer or ulcer surgery (“have you ever had …”, missing excluded). As an 
additional measure, we included use of histamine H2 antagonists (A02BA), misoprostol 
(A02BB) or proton pump inhibitors (A02BC) as a contraindication. The secondary measure 
was therefore a history of GI ulcer and/or the use of these drugs. This choice was motivated 
by a previous study, where use of “anti-reflux medications” were considered a relative 
contraindication toward NSAID use.86 
Chronic pain (Paper I-III) 
Chronic pain was assessed by the question in Q1 “Do you have persistent or constantly 
recurring pain that has lasted for three months or more?” Those who answered “yes” were 
invited to answer a section of follow-up questions in Q2. This included chronic pain duration 
(years, months), chronic pain frequency (daily/weekly/monthly/less than monthly), number of 
chronic pain body locations, and an 11-point numerical rating scale (NRS) for usual and 
maximal pain intensity. 
In paper I, the chronic pain question was used as it was reported in Q1 (prevalence: 32.8%). 
However, several participants answered Q2 despite replying “no” to the entry question in Q1. 
To account for this discrepancy and to correct likely false negative and positive replies to the 
entry question, we used information from Q2 to recode the chronic pain variable in Paper II 
and III (as described in the Supplement of Paper II); those who reported no chronic pain in Q1 
but a pain duration ≥ three months and maximal pain intensity > zero and pain frequency > 
less than once a month and at least one pain location were recoded to having chronic pain (n = 
349). Conversely, those who reported chronic pain in Q1 but pain duration < three months or 
maximal pain intensity = zero or a frequency = less than once a month were recoded to 
having no chronic pain (n = 53). The recoding increased the prevalence of chronic pain to 
35.0%. This choice was assessed by also using the original chronic pain variable in key 
analysis but this did not have a large impact on the results. 
The different dimensions of chronic pain was coded as follows: Duration: no chronic pain, ≥ 
three months and < three years, ≥ 3 and < 10 years, ≥10 and < 20 years, and ≥ 20 years. 
Frequency: no chronic pain, less than daily, and daily. Usual and maximal pain intensity: no 





10). Number of body locations: no chronic pain, one location, two to three locations, four to 
six locations, and seven or more locations. 
Psychological distress (Paper I-III) 
Hopkins Symptoms Checklist 10-item version (HSCL-10) is an instrument to measure 
psychological distress.112 The instrument consists of ten items assessing symptoms of both 
anxiety and depression during the last week. Each item gets a score ranging from one (no 
complaint) to four (very much), while the average score of the ten times provides a measure 
of psychological distress. Missing values were replaced by the mean score of the item. 
However, if three or more items were missing, the whole score was set to missing. 
Psychological distress was defined as a HSCL-10 score above 1.85.112 
Physical activity (Paper II-III) 
Physical activity was assessed by several different questions in Tromsø 6. As a measure of 
physical activity, we used the frequency of exercise assessed by the question: “How often do 
you exercise (with exercise we mean for example walking, skiing, swimming or 
training/sports)?” This was categorized into never or less than weekly, once a week, two to 
three times a week, and approximately every day. The questions on leisure time physical 
activity, including the frequency of exercise, has previously been shown to be a reasonably 
valid measure of vigorous physical activity in a comparable health survey.113 
Cold pressor test (Paper III) 
In the CPT, participants submerged their dominant hand and wrist in circulating cold water 
and held it there as long as possible, up to a maximum of 106 s.101,114 Before the test 
participants were screened, and those who were unwilling to participate, did not understand 
instructions, or had medical contraindications or risk of adverse effects were excluded.115 
Participants rated their pain intensity on NRS after four seconds and subsequently every nine 
seconds. Endurance time was recorded on hand-withdrawal. We used the CPT endurance time 
as measure of pain tolerance and a proxy measure of pain sensitivity. 
The CPT equipment consisted of a Julabo FP40-HE water bath (Julabo Labortechnik GmbH, 
Germany) from which water was pumped to an external 13-L container, with a constant 
temperature of 3.0 °C and circulation speed of 22 L/min. The intentional sample included all 
participants attending the first visit in Tromsø 6 (n = 12,984). However, due to limitations on 





due to the lower sampling rate for these age cohorts. Additionally, some subjects were 
excluded due to medical or technical reasons as described in Figure 6, creating an available 
sample for analysis of n = 10,486. 
3.3 STUDY DESIGN 
3.3.1 Paper I 
We used the Tromsø 5 and Tromsø 6 study to analyze the change in self-reported analgesic 
use over time, while the analysis of prevalence of analgesic use in high-risk groups was 
conducted in the Tromsø 6 population (Figure 4). We considered several contraindications or 
drug interactions not reported in the paper, including: asthma, heart failure, reduced liver 
function, reduced lung function/chronic obstructive pulmonary disease, age ≥ 65 (implicitly 
done), medication overuse headache, pregnancy, addiction/misuse, and alcohol use. In regards 
to the drug interactions, we decided to focus on pharmacodynamic drug interactions and 
group effects.  
 






3.3.2 Paper II-III 
For Paper II and III we linked the Tromsø 6 study with NorPD. Paper II and III generally had 
the same study design. We examined persistent analgesic use based on the aforementioned 
definition among all participants of the Tromsø 6 study (n = 12,981) within the range three 
years before to five years after attendance using NorPD (Figure 3 and Figure 5). We 
constructed a new cohort by excluding all those who had a persistent treatment episode of 
analgesics within the three years before (and including) the attendance date (n = 1,076). This 
cohort (n = 11,905) was followed for 4.5 years. 
 
Figure 5 Flow chart of Paper II. 
In paper III, we limited the study population to those who had complete CPT tolerance data (n 
= 10,486, Figure 6). The prospective study cohort consisted of 9,657 persons who were 
followed for 4.5 years. We analyzed the association between baseline pain sensitivity and 
future persistent analgesic use. In addition, we analyzed cross-sectional associations between 






Figure 6 Flow chart of Paper III. Excluded other reasons: Technical error, medical 
reasons, lack of comprehension, etc. Excluded post-test: Technical error, lack of 
comprehension, etc. 
3.4 DIRECTED ACYCLIC GRAPHS 
We employed, directed acyclic graphs (DAGs) for variable specification and model selection 
in paper II and paper III.116(pp175-9) The variables were selected based on the literature and 





Figure 7 Directed acyclic graph (DAG) of the association of chronic pain with 
persistent analgesic use and the multiple regression model used in the analysis. 
Age, sex, education, psychological distress and physical activity are considered 
confounders. The association between chronic pain and psychological distress is 
likely bidirectional, and depicted in the DAG with an unknown common cause. 
Self-reported health is not included due to the qualitative collinearity with chronic 
pain, or the role as a potential mediator, or, as shown in the DAG, a collider. 
3.5 STATISTICAL ANALYSIS 
3.5.1 Paper I 
Change in analgesic use between Tromsø 5 and Tromsø 6 was analyzed with generalized 
estimating equations with a logit link function; the analysis of the total analgesic use was a 
test of change in prevalence. However, the test in the specific prescription subgroups was not 
a test of change in “prevalence” per se but rather a test comparing “no use” in Tromsø 5 to 
use of the specific prescription category in Tromsø 6 (resembling a multinomial logistic 
regression where each level is compared separately to the base/reference level, i.e., “no use”). 
Analysis of differences in analgesic use between contraindications/drug interactions groups 





3.5.2 Paper II 
Cox proportional hazard regression was used to assess the association between baseline risk 
factors at attendance and future persistent analgesic use. The start date of the first persistent 
treatment episode was defined as the event date, while date of death or end of follow-up was 
the censoring dates. 
3.5.3 Paper III 
The prospective analysis was the same as in Paper II; we analyzed the risk of future persistent 
analgesic use with Cox proportional hazard regression. CPT endurance time was 
dichotomized into those who endured the entire test (106 s) and those who withdrew the hand 
before, and entered as an independent variable. 
Cox proportional hazard regression was also used to assess the cross-sectional associations 
between different measures of analgesic use and pain sensitivity. However, in this model CPT 
endurance time was entered as the survival time, hand withdrawal as the event and completing 
the entire test as censoring. The analgesic use measures were (separately) entered as 
independent variables, in addition to potential confounders. 
3.5.4 Software 
Stata (College Station, Texas, USA), versions 13.0-14.1, was used for all analyses. DAGs 
were created and analyzed in DAGitty (www.dagitty.net).117 
3.6 ETHICS 
This project has been approved by the Regional Committee for Medical and Health Research 
Ethics, North Norway (2012/1636). The record linkage between the Tromsø Study and 
NorPD was approved by the Norwegian Data Protection Authority (Datatilsynet, reference: 
31488/4/lt). This research has been conducted in accordance with the 1964 Helsinki 
declaration and its later amendments. Written informed consent was obtained from all 
included participants. We pursued to adhere to the Strengthening the reporting of 
observational studies in epidemiology (STROBE) statement in the conduction and the 







4.1 PAPER I 
 The age-adjusted prevalence of analgesic use last four weeks increased from 
53.7% to 59.6% in women and from 29.1% to 36.7% in men between Tromsø 5 
(2001-02) and Tromsø 6 (2007-08). Corresponding crude prevalences were 51.1% 
to 57.2% and 26.1% to 33.9%. 
 The majority of use consisted of non-prescription analgesics alone, with age-
adjusted prevalence increasing from 36.7% in Tromsø 5 to 42.9% in Tromsø 6 in 
women and from 21.3% to 27.1% in men. 
 The increase was due to an increase in use of OTC analgesics, and it seemed to be 
explained by an increase in sporadic use, i.e., a frequency of monthly or less. 
 Prevalences of regular use last four weeks of NSAIDs, other analgesics and 
antipyretics (i.e., predominantly paracetamol) or opioids were 12.7%, 12.5% and 
3.7%, respectively. 
 The prevalence of regular NSAID use in important contraindication groups were: 
chronic kidney disease: 8.6%, gastric ulcers: 12.0%, high primary CVD risk: 
11.1%, and CVD: 6.7%.  According to age- and sex adjusted logistic regression, 
the prevalence of NSAID use was only statistically significantly lower among 
those reporting a history of CVD, i.e., secondary risk, compared to those not 
reporting this contraindication. 
 The prevalence of regular NSAID use in important drug interactions groups were: 
warfarin: 2.8%, ASA, low dose: 5.8%, SSRIs: 22.0%, oral glucocorticoids: 12.6%, 
and ACE inhibitors: 6.5%.  According to age- and sex adjusted logistic regression, 
the prevalence of NSAID use was statistically significantly lower among users of 
warfarin, ASA, and ACE inhibitors compared to non-users, while it was higher 
among SSRI users.  
 The prevalence of regular opioid use was much higher among those reporting 
regular use of other CNS depressants (18.1%), i.e., benzodiazepines, z hypnotics 





4.2 PAPER II 
 The prevalence of persistent analgesic use was 4.3%  in general and 10.2% among 
those reporting chronic pain. 
 The prevalence increased with chronic pain severity and was 16.6% among those 
reporting usual chronic pain severity as severe (NRS 7-10) and 15.3% among 
those reporting chronic pain in seven or more places on the body. 
 If self-reported daily use of OTC analgesics last four weeks was included, the 
prevalence of persistent analgesic use was 5.2% in general. 
 The incidence rate of persistent analgesic use within the 4.5 years of follow-up 
was 21.2 per 1,000 person-years. 
 The median persistent analgesic user used analgesics for 382 days in total (of the 
eight-year study period; a user could have more than one episode during the study 
period), while 15.6% of persistent analgesic users had a total treatment duration 
above five years. 
 Risk factors for persistent analgesic use were chronic pain, increasing age (non-
linearly), female sex and lower education level. Although the results were less 
clear, being less physical active also seemed to be a risk factor. Furthermore, the 
risk increased in a dose dependent manner with increasing chronic pain severity, as 
measured by several chronic pain dimensions, i.e., duration, frequency, intensity, 
and number of body locations. 
4.3 PAPER III 
 Analgesic use was associated with increased pain sensitivity, i.e., reduced pain 
tolerance as measured by the CPT, at the cross-sectional level. This was 
consistently seen for all measures of analgesic use, including persistent analgesic 
use, self-reported OTC or Rx analgesic use, regular use of analgesics or analgesic 
use in the 24 hours before the CPT. 
 Regular users of opioids alone were statistically significantly more pain sensitive 
than regular users of non-opioids. Only opioid users were statistically significantly 
more pain sensitive than non-users of analgesics after adjustment for confounders. 
 Increased pain sensitivity was a risk factor for future persistent analgesic use in 
crude analysis. However, this association was non-significant after adjustment for 






5.1 DISCUSSION OF MAIN FINDINGS 
5.1.1 Prevalence and trends in analgesic use 
We found a prevalence of analgesic use last four weeks of 57.2% among women and 33.9% 
among men in Tromsø 6 (2007-08). This is higher than the previously reported prevalence 
measures in Nordic studies from the 80s and 90s,49-54 suggesting an increase in the use. 
However, all of these studies used a dichotomous measure with a two-week recall period, as 
opposed to our frequency question with a four-week recall period. A longer recall period may 
to a larger degree capture sporadic users.54 A recent Norwegian study with data from 2006-08 
reports a prevalence of OTC use of 47%.68 Although their estimate is somewhat higher than 
ours (≈ 41%), maybe due to differences in age- and sex distribution and the definition of use, 
this largely confirms our findings. Taken together, the use of OTC analgesics in the 
Norwegian adult population is extensive. 
We found an increase in the total prevalence of analgesic use between 2001-02 and 2007-08. 
Looking into this numbers, the prevalence of OTC analgesic use increased, while Rx 
analgesic use showed no statistically significant difference (crude prevalence of the Rx 
variable: Tromsø 5: 15.9% vs. Tromsø 6: 15.0%). However, the sales of both OTC analgesics 
and Rx analgesics in Norway increased between 2001 and 2008, with the largest relative 
increase for the OTC analgesics (personal communication, Christian Berg, Norwegian 
Institute of Public Health). An increase in sales may be due to an increase in the proportion of 
users, more intense treatment among users or a combination of both (or more being sold but 
never used, i.e., discarded). There is a possibility that there is a difference in the association 
between sales and prevalence between OTC and Rx analgesics. An increase in OTC sales 
could mainly reflect an increase in prevalence, while an increase in Rx sales could mainly 
reflect more intensive treatment prescribed by the physician. However, according to NorPD, 
the prevalence of use of Rx analgesics increased between 2004 and 2008.59(search:8Mar’16)  The 
prevalence before the inception of NorPD in 2004 is unknown but the prevalence of 
prescription analgesics in Denmark increased between 2002 and 2004.42. Potential 
methodological issues with our findings, like possible misclassification of OTC and Rx use, 





Three recent studies with repeated cross-sectional design are particular relevant to our 
study.70,71,81 Ruscitto et al. report an increasing prevalence of any prescription analgesic use in 
Scotland from 16% to 18% between 1995 and 2010.70 Paracetamol, gabapentinoids and 
opioid use increased, while the use of ASA and non-selective NSAIDs decreased. 
Interestingly, the proportion reporting use of multiple analgesic drug classes was higher in 
2010. Sarganas et al., with data from 1998 to 2008-2011, report findings in Germany that are 
strikingly similar to our results.71 The prevalence of analgesic use (here: ASA, diclofenac, 
ibuprofen, naproxen, paracetamol) increased from 19% to 21%. Although the prevalence 
estimates cannot be directly compared, the increase was, as in our study, explained by an 
increase in the use of OTC analgesics only. Finally, Zhou et al. report an increasing trend of 
regular ASA and NSAID use in the USA, with prevalences increasing from 12% to 19% and 
9% to 13%, respectively, between 2005 and 2010.81  
The sales of NSAIDs has been relatively stable in Norway in the years after the steep drop in 
sales after the Vioxx case (2004).45 In Denmark, the prevalence of prescription NSAID use 
increased until 2004, while it has been decreasing thereafter.12 In recent years several studies 
have shown an increasing use of opioids,66,67,69,70 sometimes referred to as the “opioid 
epidemic”. 
In summary, analgesic use has increased over the last three-four decades. The reasons for this 
increase could be several, including better treatment of pain, increasing prevalence of pain, 
increasing longevity, increased availability, introduction of new analgesics or new indications, 
and marketing.  
Increasing analgesic use may be explained by an increasing prevalence of painful conditions, 
e.g., musculoskeletal chronic diseases, as suggested by others.70,71 The prevalence of chronic 
pain may be increasing.119 The first study to evaluate the chronic pain prevalence in Norway 
reports a prevalence of 24% in 2000,119 compared to our finding of 33-35% in 2007-08. A 
direct comparison of the prevalence estimates, however, is limited due to methodological 
reasons.120 Nevertheless, increased attention to pain from prescribers and better pain 
management, in addition to increased awareness and higher expectations and demands from 
patients, may be more likely driving forces than the underlying prevalence of pain.70,76 
Marketing of analgesics, particularly when new analgesics are introduced, could explain some 





increased sales of opioids observed in the Nordic countries in 2002-06.48 The sales of 
NSAIDs increased pronounced after the introduction of the COX-2 inhibitors around 2000.45 
We and others have suggested increased availability as a factor in the increased use.71 In 
Norway, there was a vast increase in the number of pharmacies after the deregulation of the 
pharmacy sector and the abolishment of the pharmacy monopoly in 2001.121 Furthermore, 
ibuprofen and paracetamol was released to general sales outside pharmacies in 2003.121 In 
Australia, the prevalence of use of OTC NSAIDs (i.e., ibuprofen) increased between 2001 and 
2009 after ibuprofen was switched to general sales status in 2004.87 However, in the same 
period there was an increase in OTC analgesic use also in Germany, where the OTC 
analgesics are only available in the pharmacies or internet pharmacies.71 
5.1.2 Persistent analgesic use 
We found a point prevalence of persistent analgesic use of 4.3% and an incidence rate of 21.2 
per 1,000 person-years. Assuming a relatively stable incidence rate, the period prevalence can 
be derived from the formula:122 
	 	 	 	 	 	  
Substituting the estimates from our cohort, i.e., closed population, into this formula produces 
a one-year period prevalence of slightly above six percent in the year after attendance. 
However, this must be viewed as a crude approximation based on a simplification, as the 
formula assumes a steady-state, while there is no simple relation between prevalence and 
incidence.123(p136)  
 As this is, to my knowledge, the first study of persistent analgesic use that includes all of the 
major analgesic groups, there is not much to directly compare with in the literature. 
Nevertheless, the point prevalence of persistent opioid use in Norway is around 1% (>180 
DDD or >4500 mg oral morphine equivalents per year and prescriptions in three out of four 
quarters of a one year period, palliative treatment excluded) 14,79 and the one-year period 
prevalence of heavy NSAID use (≥ 182 DDDs/year) in Finland is 1.5%.57 These definitions, 
while not identical to ours, try to capture the same “type” of persistent users. Fredheim et al. 
furthermore report a prevalence of persistent opioid use of 8% among those with severe/very 
severe chronic pain (chronic pain defined as at pain lasting at least six months and at least 
moderate intensity during the last week).79 In comparison, we found a prevalence of general 
persistent analgesic use of 17% among those reporting usual chronic pain intensity as severe. 





compare these figures directly. Boudreau et al., using a method and definition that we partly 
based our definition on, report a one-year period prevalence of persistent opioid use in the 
USA of 4-5% and an incidence rate of persistent opioid use around 9-12/1,000/year.76 In our 
data, the incidence rate of any analgesic use was around 10 times higher than the incidence of 
persistent analgesic use (data not shown). Boudreau et al. report an increase in both period 
prevalence and incidence of persistent opioid use in 1997-2005.76 The point prevalence of 
persistent opioid use increased slightly during 2005-07 in Norway.14 We also observed an 
increasing prevalence of persistent analgesic use within the study period. 
Patients most often use NSAIDs as a single course of treatment (i.e., dispensed once) of short 
duration,11,13 which is probably generalizable to the use of other analgesics. The vast majority 
of analgesic users therefore seem to consist of one-time or recurrent users with short treatment 
duration, while the prevalence of persistent analgesic use is relatively low. However, the 
relatively few persistent analgesic users seem to contribute to a considerable amount of the 
prescription volume of analgesics. 
The duration of treatment can, under the aforementioned assumptions, be calculated as: 122 
	
1 	 	 	 	
 
Based on our estimates, the derived average duration of persistent analgesic use is therefore 
around 2 years. The average total duration of the persistent treatment episodes in the study 
period (i.e., the sum of all persistent treatment episodes for an individual) were also around 2 
years. Although relatively few seems to use analgesics persistently, some use them for years 
on end. 
Among those who reported chronic pain, 10% were defined as persistent users of prescription 
analgesics. In a Norwegian study, 42% of those with chronic pain treated their pain with 
analgesics, 32% physiotherapy and 31% no treatment,119 while a Swedish study reports that 
62% of those with chronic pain used analgesic last two weeks.92 As we have shown, the use of 
OTC analgesics is extensive. If we, for example, included self-reported daily or weekly use of 
OTC analgesics in addition to persistent Rx analgesic use, almost one third of those with 
chronic pain used analgesics. Set aside the uncertainties of these estimates, our study suggest 
that a minority treat their chronic pain with analgesics persistently. This is consistent with the 
undocumented and low level of effectiveness of analgesics in chronic pain. Based on the 





responders may be small but when treatment response is achieved, it tends to last.30 Adding to 
that, are the many and potential serious adverse effects leading to a high discontinuation rate. 
The group of persistent analgesic users may therefore consist of a dually selected group of 
responders to long-term treatment who at the same time do not experience troublesome 
adverse effects. However, we cannot based on our study say that the prevalence of persistent 
analgesic use represent a “correct” level. Chronic pain may be undertreated and there may be 
individuals who may benefit from persistent treatment that have not been reached. A final 
possibility is that some may use analgesics inappropriately, e.g., addiction, pharmacological 
irrational use, and where the need for persistent treatment should be reassessed and probably 
discontinued. 
5.1.3 High-risk use 
Several studies report a higher prevalence of NSAID use among those with a history of 
CVD8,81,86 compared to those who do not have CVD. This is in contrast to our findings, where 
the prevalence was lower in the group with a history of CVD. This may reflect differences in 
awareness of contraindications against NSAID use. However, these findings may be 
confounded by age. NSAID use increased by age in the aforementioned studies.8,81,86, while 
we found a decreasing prevalence with age, in line with an Italian study.64 A decreasing age 
trend has also been reported for OTC NSAID use,68 suggesting that the trend we observed 
was mainly driven by OTC use. As those with a history of CVD are older than those without, 
this could partly explain the difference between the studies. After adjusting for age and sex in 
our study, the prevalence of NSAID use was still statistically significantly lower among those 
with a history of CVD compared to those without. In a study of the Danish population, 
previous myocardial infarction or ischemic heart disease were associated with reduced odds 
of being prescribed NSAIDs.11 
A previous study found no difference in NSAID use between those who were aware of their 
CKD or not.124 However, the prevalence of current use was slightly higher among those with 
CKD compared to those without. In our study, the crude prevalence was lower among the 
CKD group, while there was no statistically significant difference after adjustment for age and 
sex differences. In a recent study, reporting of eGFR reduced the prescribing of NSAIDs, 
while the eGFR improved considerably after discontinuation, particularly among those with 
the most severe CKD.125 These results underline the importance of monitoring the renal 





A few studies report a higher NSAID use among those with a history of gastrointestinal 
ulcers,8,81 compared to those who do not have gastrointestinal ulcers. Zhou et al. further 
analyzed this by multivariable regression and found that ASA or NSAID use was not affected 
by the presence of peptic ulcer disease,81 in support of our findings. 
In terms of GI bleeding risk and potential drug interactions, we found a pronounced lower 
prevalence of regular NSAID use among those reporting use of anticoagulants, and warfarin 
in particular, compared to non-users of these drugs. The prevalence of NSAID use was similar 
among those with or without concomitant use of oral glucocorticoids, while the prevalence of 
NSAID use was much higher among SSRI users compared to non-users. In a Finnish study, 
the odds of being prescribed concurrent prescriptions of drugs increasing the GI bleeding risk 
was five times higher among continuous NSAID users compared to non-continuous users. 
The odds ratios, however, were lowest for warfarin (1.8), followed by SSRIs (3.6) and 
glucocorticoids (8.0).83 This suggests greater awareness of the interaction between NSAIDs 
and anticoagulants, than between NSAIDs and SSRIs or glucocorticoids, respectively. The 
strikingly high NSAID prevalence among SSRI users in our study is possibly explained by 
comorbidity between depression and pain. 
Paracetamol use has received considerable attention lately, both in terms of possible adverse 
cardiovascular effects40 and the potential of liver damage.126 US studies report that about one 
percent of the population use paracetamol in doses exceeding the maximum dose,88 and that 
hepatotoxic adverse effects of paracetamol continue to be a public health burden.126 Increased 
availability of paracetamol may be associated with paracetamol overdoses and self-
poisoning.37(pp210-1) Because of this, the regulatory authorities in Sweden have recently (2015) 
withdrawn OTC paracetamol tablets from general sales (supermarkets, petrol stations, etc.).127 
However this has so far not been deemed as necessary by the Norwegian authorities.128 The 
sales of Rx paracetamol has increased considerably in Norway the last 10 years, while the 
sales of OTC paracetamol remains more or less at the same level.128 Unfortunately, our study 
was unable to provide insight into this question, as we lacked frequency and dose of 
paracetamol use. However, we found that 12% of regular users of paracetamol-containing 
drugs reported use of more than one paracetamol-containing drug (brand), which could 
increase the risk of hepatotoxicity. The knowledge of which drugs contain paracetamol seems 
limited in the general population.88 Nevertheless, the main finding of our study was that there 
is considerable high-risk use of NSAIDs. Restriction of NSAIDs to “pharmacy only” status 





use.89 In terms of availability, a restriction on OTC paracetamol sales would have little effect 
if the possible increase in cases of paracetamol-induced liver failure is linked to Rx use.129 
Such restriction may lead to higher NSAID use.37(p210),129 Reduced paracetamol availability in 
two recall periods in Australia led to an increase in calls to poison centers regarding self-
poisoning and accidental pediatric ingestions of ibuprofen.130 Based on our findings and the 
safety profiles of NSAIDs, increased use of NSAIDs would thus represent an unwanted 
development. 
We could not separate OTC use from Rx use in our measure of regular analgesic use, 
although the declining age trend and a comparison with the frequency questions suggested 
that the majority of regular NSAID use was due to OTC use. On the one hand, this is 
reassuring since the approved OTC dose is lower than the Rx dose, while the risk of adverse 
effects is higher in the elderly. On the other hand, this adds to the previous findings of a lack 
of awareness of the risks associated with OTC analgesics.89 Potential high-risk use of OTC 
analgesics has been reported in a range of studies.56,82,84,87,89 Furthermore, the use of doses 
above the recommended dose has been reported among OTC NSAID users.84,89 Inappropriate 
use of OTC analgesics coupled with easy access to these drugs may put people at risk, 
underlining the importance of monitoring the utilization patterns on a population-level. 
A question remains if our findings from 2007-08 are still valid today. The sales of NSAIDs 
remain close to the same level in 2014 as in 2008 (a slight increase). However, there has been 
more pronounced internal changes within the group, with diclofenac showing a decrease and 
naproxen an increase (mostly due to introduction of naproxen + esomeprazol).44,45 In 
Denmark, the prevalence of Rx diclofenac was halved between 2008 and 2012.12 This is 
favorable in terms of cardiovascular risk. However, in the last couple of years, the sales of 
COX-2 inhibitors is once again increasing in Norway after a regulatory change in 
reimbursement.45 Likewise, increasing use of naproxen, as one of the NSAIDs producing the 
highest risk of GI ulcers, would require even more effort in identifying high-risk groups and 
the use of prophylactic drugs against ulcers. 
5.1.4 Risk factors for analgesic use 
The identified risk factors for persistent analgesic use were chronic pain, increasing age, 
female sex and lower education level. This was generally consistent with previously reported 
risk factors for analgesic use in general. The associations with low levels of physical activity 





statistically significant in crude analysis only. However, the point estimates did not change 
substantially in the multiple regression suggesting power as an explanation of this null 
finding. The notion that physical inactivity indeed is a risk factor was corroborated by using 
other variables on physical activity (data not shown).  
The risk of persistent analgesic use increased with increasing chronic pain severity (Paper II). 
In Paper I, we found a gradient of worsening health and more pain over the different 
prescription categories, with concomitant users of OTC and Rx users generally scoring worse 
than users of Rx analgesics alone, which again was worse than users of OTC analgesic alone.  
5.1.5 Pain sensitivity and analgesic use 
Analgesic use was associated with increased pain sensitivity on the cross-sectional level. 
Increased pain sensitivity was a statistically significant risk factor for future persistent 
analgesic use only in the crude analysis. The interpretation of these findings is challenging. 
Following the proposed hypothesis by Edwards,94 highly pain sensitive individuals have a 
greater risk of developing chronic pain. We have shown that chronic pain is, as expected, a 
risk factor for using analgesics persistently, suggesting that increased pain sensitivity would 
not only be a risk factor for chronic pain but also subsequent analgesic use. The most pain 
sensitive subjects may be more likely to seek help, i.e. the prescribing physician, and to be 
diagnosed with chronic pain. In that sense, increased pain sensitivity may not be a direct part 
of the etiology of chronic pain, but rather increases the likelihood of being diagnosed with 
chronic pain.19  
However, the pharmacological effect of analgesics may be reduced among subjects with 
increased pain sensitivity. In that sense, increased pain sensitivity may be a marker of a 
dysfunctional endogenous pain inhibitory system, which at the same time may be a risk factor 
of chronic pain and of reduced effectiveness of the classical analgesics. The most pain 
sensitive subjects may have more centralized pain phenotypes, e.g., fibromyalgia or 
neuropathic pain that are particular resistant toward treatment with analgesics.131 This is 
further complicated by the possibility that analgesic use in itself may cause hyperalgesia and 
increased pain sensitivity, and in particular opioid-induced hyperalgesia. Additionally, 
another hypothesis suggests that long-term COX inhibition by NSAID use may lead to 
suppression of anti-inflammatory lipid mediators and paradoxically increased pain.17,132  
In our study, opioid users seemed to be more pain sensitive than NSAID users, whom again 





pain sensitivity due to analgesic use, a more plausible explanation is the severity of the 
underlying pain, e.g., treatment with analgesics according to the WHO pain ladder.133 For 
instance, those reporting concomitant use of OTC and Rx analgesics seemed more pain 
sensitive than users of OTC alone. Our measure of regular use did not separate between OTC 
or Rx use, but as opioids are only available on prescription in Norway, the “opioids only” 
group would represent use of Rx analgesics only, while the other groups would represent a 
mixture of OTC or Rx use (although, as previously mentioned, the majority seemed to be 
regular OTC users). Furthermore, it would be difficult to separate pre-existing hyperalgesia 
from OIH,134 particularly on the cross-sectional level.  
We can only conclude that increased pain sensitivity is a characteristic associated with an 
increased probability of analgesic use, and as such is a risk factor after the definition used in 
this dissertation (although at the cross-sectional level the opposite may also be true: analgesic 
use is a risk factor for increased pain sensitivity). The main explanation seems to be increased 
pain sensitivity associated with the severity of the underlying pain, i.e., the indication for use 
of the analgesics, perhaps suggesting that the most pain sensitive subjects are those who have 
the greatest likelihood of seeking professional help. However, when it comes to potential 
causal pathways and mechanisms, future studies are needed. In recent years, there has been a 
growing interest in quantitative sensory testing and experimental pain tests in relation to 
analgesic use. Particularly, if experimental pain tests can be used to predict treatment response 
to analgesics135,136 and in mechanism-based treatment of pain.137 
5.2 METHODOLOGICAL CONSIDERATIONS 
5.2.1 Selection bias and external validity 
Selection bias is a systematic error in estimated associations between exposure and outcome 
which is caused by the procedures used to select subjects into a study or an analysis.91 
Another definition emphasizes that selection bias, or “sample distortion bias”, occurs when 
the included subjects in a study is not representative of the larger population one wish to 
extrapolate the results to, i.e., exposures or outcomes of interest in the study sample are over-
represented or under-represented.90 Others argue that systematic differences between the 
study population and other populations is not selection bias, but “sampling bias” and refers to 
the generalizability or external validity of the findings.91 No matter the nomenclature, non-
response or non-participation bias is of particular relevance to health surveys. It occurs when 





study population must be representative of the source population to produce valid prevalence 
and incidence estimates. Furthermore, if the likelihood of participation in a health survey is 
conditional on the exposures and/or the outcome under study, measures of associations can 
also be biased. 138 
The source population of the Tromsø Study is the inhabitants of the municipality of Tromsø, 
with a population size of around 65,000 at the time of Tromsø 6. Although the sampling 
procedure of the Tromsø Study is complex, involving a mix of participants from previous 
waves, whole birth cohorts and random samples, the purpose is to produce a sample that is 
representative of the source population. However, the attendance rate in Tromsø 6 was 66%, 
with higher attendance rate among women than men.101 The participation rate in Tromsø 6 
was somewhat higher than in comparable contemporary health surveys.101 It is, however, not 
the participation rate itself that determine the degree of bias in a study but rather the 
differences between the participants and non-participants.139 Non-participants of the Tromsø 
Study tend to be younger, single and have a higher male to female ratio.102 In a similar 
Norwegian health survey, the Nord-Trøndelag Health Study (HUNT), the prevalence of 
several chronic diseases were higher among non-participants, while the prevalence of 
musculoskeletal pain and headache were, perhaps surprisingly, lower among non-
participants.138 Taken together, this would suggest lower analgesic use among 
nonparticipants. On the contrary, a previous study based on Tromsø 3 (1986-87) reports 
higher use of controlled analgesics (mainly combined codeine analgesics) among non-
participants compared to participants.62 The period prevalence of analgesic use reported in 
Paper II was reasonably comparable to those reported for Troms County. In the HUNT study, 
inclusion of non-participants generally led to only small changes in the overall prevalence 
estimates.138 Galea et al. conclude that “most empiric work suggests that declines in 
participation rates are not likely to have substantial influence on exposure-disease associations 
or point estimates of measures of interest”.139 In summary, the somewhat conflicting evidence 
makes it hard to conclude if, and how, non-participation bias has affected our estimates of 
analgesic use. However, there is reason to believe that non-response bias is of minor concern. 
If non-response bias is present, this has most likely led to an underestimation of analgesic use, 
based on the general assumption that less healthy subjects are less likely to participate.138 
In terms of generalizability to the total Norwegian population, the total sales of analgesics 
(M01, N02A, N02B) in Troms County was slightly lower (about -3%) than the country 





validity to other populations, The Tromsø population is considered a typical Northern 
European, predominantly Caucasian, urban population,101 and our findings may be 
generalizable to similar populations. 
5.2.2 Information bias and recall 
Information bias is a systematic difference in the collection of information or measurement of 
variables between comparison groups, resulting in biased estimates or a distorted association 
between exposure and outcome.90,91 Recall bias is a type of measurement or information bias 
that relates to the study participants’ ability to recall or remember past events or experiences, 
and systematic differences between comparison groups occurring as a result.90,91 Recall bias is 
of particular concern in case-control studies but the term is also used more generally in the 
context of self-reported measures, e.g., questionnaires. Random differences in the recollection 
of events, i.e., no systematic differences between comparison groups, leads to a loss of 
precision but not bias.90 The consequence of information bias, however, is misclassification of 
the exposure and/or outcome variables.140(p121) 
Poor recall in the self-reported analgesic use measures could therefore introduce bias and/or 
lead to a loss of precision. Recall and accuracy of drug use is reported to be better for 
prescription drugs than OTC drugs.141(p769) Likewise, drugs used chronically, and especially 
frequently dispensed drugs, are more likely to be recalled than acute use.141(p769) Recall of 
infrequent use of OTC NSAIDs is worse than frequent/repeated use, and data on frequent use 
thus seems more reliable than infrequent use.142 Furthermore, the recall declines with 
increasing length of the recall period or with time passed since the drug was used.141(p769),142 
On the contrary, too short recall periods increases the likelihood of missing occasional drug 
users.143 In terms of issues relating to poor recall, prescription registries provide an advantage, 
since registration is independent of the subject’s memory or ability to recall. In our studies, 
self-reported infrequent use of OTC analgesics is most likely to be affected by poor recall, 
which may have resulted in underreporting. 
The choice of questions and the design of the questionnaire will affect the response. In a 
cohort study, the use of three different ways of asking about analgesic use produced large 
variation in the prevalence; a measure asking respondents to name/list their analgesic drugs 
produced the highest prevalence, followed by a symptom-oriented measure, while a frequency 
measure produced the lowest prevalence.144 Drug-specific and indication-specific questions 





ended questions on drug use.141(p769),145 Combining different measures could increase the 
completeness.144 Providing examples, like drug photos, or drug names, could also increase the 
response.141(p769),145 Finally, the ordering of the questions or items may affect the response. 
For instance, drugs listed early in a questionnaire have a higher likelihood of being selected, 
known as the primacy effect.141(p769),145  
Dichotomous measures of analgesic use, as used previously in a range of studies, 49-54 have 
the disadvantage of not separating chronic and infrequent users.54  In a study based on other 
Norwegian surveys with similar frequency questions on analgesic use as in our study, the 
authors argue that most of “the attendees found the answering categories suitable for their 
pattern of use” and that they had a high willingness to participate based on the high response 
rate.143 
In addition to misclassification due to recall, there may also be misclassification according to 
the prescription status. There were separate questions on OTC and Rx analgesic use, 
respectively, in Tromsø 5 and Tromsø 6. However, no examples or definitions of OTC or Rx 
analgesics were provided in the questionnaires. The two most sold OTC analgesics, ibuprofen 
and paracetamol, are also available as (larger) Rx only packages. These Rx only packages 
may be misclassified as OTC analgesics. On the other hand, it is less likely that an exclusive 
Rx analgesic, e.g., tramadol, is misclassified as an OTC analgesic. 
5.2.3 Missing data 
Missing data is a potential source of bias. The mechanism or pattern of missing are usually 
divided into missing completely at random (MCAR), missing at random (MAR) and missing 
not at random (MNAR), depending of the difference between observed and missing values; in 
MCAR there are no systematic differences, in MAR the differences can be explained by the 
observed data, while in MNAR the differences cannot be accounted for by the observed 
data.146(p432) In the face of missing data one is left with the options of either excluding 
individuals with missing or replacing the missing data using imputation. The choice of 
method is based on the proportion of missing and the assumed missing data pattern. If the 
proportion of missing is very low (some have suggested < 5%, although a general rule does 
not exist), exclusion of missing is not likely to produce substantial bias.146(p437) If the 
proportion of missing is large and/or not believed to be MCAR, multiple imputation is a 





Complete case analysis (“listwise deletion”) refers to restricting the analyses to individuals 
with complete data, i.e., on all variables in question. The advantage is that the sample size 
remains the same across analyses, making estimates directly comparable. The disadvantages 
are that substantial number of individuals may be lost, i.e., reduced power, if the combined 
proportion of missing is high, while bias may be introduced if the missing individuals differ 
from those who are completely observed.147(pp15-8) Another common approach is the available 
case analysis (“pairwise deletion”). 148 In this method, the maximum number of individuals 
with non-missing variables are included in each particular analysis, i.e., sample sizes differ 
between analyses.146(p437),148 The advantage is that the data is fully utilized. The major 
disadvantage is that the analyses are based on different subsets of the data leading to 
inconsistency in the inferences based on the estimates. Available case analysis is also 
inefficient and could introduce bias.147(pp15-8) 
A relatively common practice when working with questionnaire data is to impute missing as a 
negative response, as previously done in studies on analgesic use using self-reported 
dichotomous measures.50,51 This assumption is based on the observed pattern that some 
participants seem to only answer the questions that are relevant to them, and leave the rest 
blank. Although this approach produce a conservative prevalence estimate, this is in fact an 
ad hoc single imputation. Single imputation, in general, leads to an underestimation of the 
standard error, and do not take into consideration the uncertainty of the imputed missing 
values.147(p19) 
In this dissertation, the analyses were based on available case analyses, i.e., differing n values 
between analyses. The prevalence measures reported were the proportions after exclusion of 
missing, i.e., missing was not assumed to be a negative response. In general, the proportion of 
missing in the included variables was low, and we did not deem multiple imputation as 
necessary. In the statistical analysis section of paper I, the analyses were imprecisely reported 
to be “complete case analyses”. Although this is strictly speaking not wrong when referring to 
the statistical software, this is misleading when it comes to the study design, as the reported n 
values evidently vary. 
In terms of the questions on self-reported OTC or Rx analgesic use, the missing groups tended 
to be older, have a higher proportion of women, poorer health, lower education, and more 
pain or discomfort, compared to responders. Furthermore, the prevalence of persistent 
analgesic use, which was derived externally from NorPD, was 1.5-2 times higher among the 





equaling no use does not hold for these particular questions. Furthermore, it is plausible that 
analgesic use, for some people, may be stigmatized especially when the analgesic use has 
become problematic, leaving the respondent to either leave the question blank or reply as a 
non-user. However, the fundamental challenge with missing data is that the true status of the 
missing individuals is unknown. 
The total proportion of missing on the self-reported OTC/Rx questions, i.e., missing on either 
or both questions, was higher in Tromsø 5 compared to Tromsø 6. If the MCAR assumption 
does not hold, this may have introduced bias in the analysis of change over time. However, 
sensitivity analyses by imputing missing in these questions as non-user or user, respectively, 
were generally consistent with the main results, with the aforementioned limitation of ad hoc 
imputations in mind. 
Finally, a more subtle missing problem relates to the use of NorPD data in Paper II and III. 
Some prescriptions recorded in NorPD lack the personal identification number (PIN). As our 
study design was based on a record-linkage dependent on the PIN (i.e., the pseudonymized 
key), analgesic prescriptions registered without the PIN are not captured.103 For example, 1.6-
2.4% of opioid prescriptions in Norway 2004-07 lacked the PIN.58 Persistent users are more 
likely to have been registered with the PIN, due to more frequent visits to the 
physician/pharmacy, reimbursement and stricter control of controlled analgesics. The lack of 
PIN for a small proportion of prescriptions may nevertheless have led to a slight 
underestimation of the prevalence, particularly the period prevalence of any use. However, for 
the estimation of persistent analgesic use we consider this source of error to be practically 
negligible. 
5.2.4 Definition of persistent analgesic use 
One of the key challenges with dispensing data is to define periods of drug use. The only 
things that are absolutely certain are the dispensing dates, type of drug, amount etc. – the rest 
is based on assumptions about the subsequent use. There may be gaps between the dispensing 
date and the actual use of the drug, if it is used at all.141(p760) It is challenging to estimate the 
point prevalence of drug use based on prescription data, as many users show an irregular 
dispensing pattern, making it difficult to separate long-term users from infrequent or episodic 
users.149 Furthermore, there may be seasonal variations in actual drug use throughout the year, 





to reimbursement, e.g., dispensings at the end of the calendar year due to no co-payment (in 
Norway: “frikort”). 
No universal definition of long-term or persistent drug use exist. A definition of persistent use 
obviously needs to capture some aspects of use over time. However, a definition based 
exclusively on time between dispensing dates of prescriptions will not differentiate between 
low or high intensity use. Likewise, a definition based on intensity of use, e.g., a certain 
amount of DDDs per calendar year, will not fully differentiate high-intensity use over a 
shorter period from low-intensity use over a longer period. It has therefore been suggested 
that a persistence definition should be two-dimensional, quantifying both duration and 
intensity of drug use, more specifically through an hybrid of the refill-sequence method and 
the PDC method.106 In the refill-sequence method, the time between a first prescription and an 
unacceptable gap between refills is calculated, allowing for some given gap between refills, 
i.e., “grace period”. The PDC method calculates the number of days with available supply of 
drugs within a fixed interval, with a given cut-off for the proportion, e.g., 80%, defining 
persistence. Other methods for determining persistence are the anniversary method, i.e., the 
use of the drug within an interval surrounding the “anniversary” from the first prescription 
and the minimum-refills method that defines a minimum number of prescriptions per year.106 
When the calculated duration of two prescriptions overlap, one can choose to add the number 
of overlapping days, or disregard the overlap. In the case when a drug is switched it is 
reasonable to disregard the overlap.151 The validity of the chosen definition should be 
assessed with sensitivity analyses, i.e., varying key assumptions of the definition.152 
Defining persistent drug use is challenging for drugs used regularly, e.g., statins, and even 
more challenging for drugs with a predominantly irregular pattern or which are taken 
sporadically.152 Chronic analgesic use has previously been defined as the dispensing of at 
least 90 DDDs, under the assumption that this is “equivalent to 90 days of drug use at 
standard doses”.153 Other studies have used ≈ 180 DDD per year, representing use of at least 
0.5 DDD per day/half of the days in a year.14,57 The assumption of 1 DDD/day has also been 
used for other drug groups, e.g., single dispensings of antiepileptic drugs.154 However, the 
assumption of one DDD per day is less likely to hold for drugs us on as-needed basis and for 
symptomatic treatment, e.g., analgesics. Preliminary analyses of the mean number of 
DDD/day (data not shown) suggested that the individual analgesics have a mean dose below 
one DDD/day, which would imply that the assumption of one DDD/day would underestimate 





one DDD/day. The estimation of treatment episodes with analgesics should therefore be based 
on individually calculated average doses, and not rely on assumption of fixed doses.150 
Finally, the actual consumed dose may be different than the dispensed dose or the DDD, e.g., 
different patient groups or low adherence.150 
Repeated opioid use has been defined as four or more prescriptions per year, i.e., the 
minimum-refills model.155 Persistent opioid use has been defined as dispensing of an opioid in 
consecutive years and > 365 DDDs in the  last year of the study.156 More complex methods, 
e.g., dynamic calculation of daily dosage, definition of typical dosages, daily dosage based on 
number of tablets, etc., have been used in the estimation of NSAID use.11,157 
Svendsen et al., in their definitions of persistent opioid use, employed three dimensions of 
opioid use: intensity of use, i.e., amount dispensed, distribution, i.e., number of quarters of a 
year, and, in their strictest definition, frequency, i.e., number of prescriptions per year.14 
Likewise, Von Korff et al. defined persistent opioid use by treatment duration, number of 
prescriptions and a measure of amount, i.e., days supply.75 
Our definition was based on the works by Poluzzi et al.104,105 and Von Korf et al.75 and 
included three criteria: gap length between prescription fills, duration of the treatment episode 
and PDC, i.e., intensity of use. As no universal definition of persistent analgesic use exists, 
the choice of cut-offs are arbitrary. However, we based our choices on tacit knowledge from 
the pharmacy, the literature and sensitivity analysis, as described below. 
First, we chose a treatment duration ≥ 90 days, i.e., three months. This was partly based on the 
Norwegian reimbursement system where one is allowed to collect a maximum of three 
months’ supply of drugs each time for reimbursed prescriptions. Likewise, we wanted the 
definition to be analogous to the chronic pain question in Tromsø 6, i.e., “persistent or 
constantly recurring pain lasting three months or more”. Finally, 90 days has been used in the 
study by Von Korff et al.75  
The second criteria was the gap length. For prescriptions to be included in the same treatment 
episode the gap between the prescriptions had to be ≤ 180 days, i.e., six months, also used by 
Von Korff et al.75 A gap length twice of the “three-month-rule” used in the pharmacies 
seemed reasonable. This was supported by published work based on the waiting time 
distribution that shows that each NSAID or opioid analgesic prescription has an average 





The third and final criteria was PDC. We chose a cut-off of ≥ 40%, which was based on a 
range of sensitivity analyses (see the Supplement of paper II) and what we felt would be a 
clinical relevant cut-off (Table 4). The PDC cut-off was chosen to represent a minimum cut-
off of persistent analgesic use; a higher cut-off would lead to a lower prevalence (as shown in 
the sensitivity analysis in the Supplement of Paper II) and an even more selected group of 
high-intensity persistent users. There is not much support in the literature but cut-offs in the 
range 50-80% have been used for drugs used more chronically, i.e., antihypertensive drugs, 
statins or antidepressants,106 including when the unit of measure is the DDD.105 A previous 
study used a medication possession ratio (equivalent to the PDC) of ≥ 50% for regular 
analgesic use and ≥ 25% for occasional analgesic use.159 
 
Table 4 Clinical scenarios of the definition of persistent analgesic use. The table 
shows the minimum number of tablets per year or per week for selected 
analgesics, common tablet sizes and possible combination use of analgesics. The 
assumption is a treatment duration of 365 days and a proportion-of-days-
covered ≥ 40%, i.e., ≥ 146 DDD dispensed in these 365 days.  
 
We did not use the number of prescriptions within a treatment episode as a criterion. A 
persistent episode could therefore consist of only two prescriptions dispensed within 180 
days, as long as the duration was ≥ 90 days and PDC ≥ 40%. The proportion of persistent 
treatment episodes consisting of only two prescriptions was around 10%; the proportion 
decreased by increasing PDC cut-off. This means that our definition may have included use of 
a more episodic nature. The prevalence of persistent analgesic use was one percent among 
those not reporting chronic pain, suggesting inclusion of analgesic users for pain of shorter 













Paracetamol 3000 1000 438 8 
Ibuprofen 1200 600 292 6 
Paracetamol/codeine 4 tablets 400/30 584 11 
Paracetamol + ibuprofen (50% + 50%) See above See above 219 + 146 4 + 3 
Paracetamol/codeine + paracetamol (25% + 75%) See above See above 146 + 329 3 + 6 





prescriptions within a treatment episode and/or setting a higher PDC cut-off. The number of 
prescriptions within a persistent treatment episode is thus a useful additional criterion to 
explore in future studies. 
We chose to combine the use of either NSAIDs, paracetamol (i.e., other analgesics and 
antipyretics) or opioids into a joint measure. This meant that we treated all prescriptions 
within these groups as an “analgesic” prescription, and prescriptions dispensed on the same 
date were collapsed into one, i.e., the DDDs were summed. The rationale behind this decision 
were: 1) we wanted an overall measure of analgesic use, 2) we wanted to capture those who 
combined different analgesic groups, and 3) capture those who switched analgesic groups 
during treatment. Based on clinical guidelines and practice, and one-year period prevalences 
(see Supplement of Paper II), the use of more than one analgesic group is to be expected in 
the treatment of chronic pain. As an example, a person may use both paracetamol and 
tramadol but not in a sufficient amount that any of the drugs reach the persistence threshold 
alone. However, the combined use of these analgesics reaches the threshold. 
The main limitations of this approach are that it relies on the DDD and the assumption that the 
DDDs are equianalgesic, and it combines different analgesic drugs into a single measure, 
regardless of differences in for example DDD/day for different substances. For the opioids it 
has previously been shown that the assumption of equianalgesia for one DDD between 
different opioids is less than optimal, and that the use of morphine equivalents could be used 
as a replacement or an addition to the DDD.160 However, as our study did not focus 
exclusively on opioids and since there exist no conversion factors of analgesic equivalency 
between the main analgesic groups, morphine equivalents was not an option, leaving us with 
the DDD as the best approach.  
5.2.5 Validity and agreement of the analgesic use measures 
In this context, validity (or accuracy) refers to a comparison with a gold standard, while 
agreement refers to a comparison between different methods for data collection were neither 
source is superior.141(pp758,760) Prescription databases and pharmacy dispensing data are 
commonly considered to have a high accuracy and to be the gold standard for data on drug 
use.152 
The agreement between self-reported analgesic use and dispensing records is generally 
moderate (κ ~ 0.5), with higher agreement when the fixed-time method is used.161,162 





measurements of metabolites in urine finds a rate of underreporting of 15-17%.163 In all, this 
suggests that self-reported analgesic use is subject to underreporting, while overreporting is 
less common.161 We conducted no formal validation study of the analgesic measures used. 
However, in preliminary analyses the agreement between self-reported Rx use and 
prescription registry data (e.g., dispensings last six months, our persistence definition etc.) 
was similar to the cited previous reports, i.e., around moderate agreement. Potential reasons 
for limited agreement between self-reported drug data and dispensing data include poor 
adherence, inaccurate reporting (e.g., recall bias, unwillingness to participate, and stigma) and 
the previously discussed methodological issues, like questionnaire design, conduction of the 
interviews, and definition of drug use.161,162 
We used several different measures of analgesic use. The point prevalence of persistent Rx 
analgesic use was four percent, daily or weekly self-reported Rx analgesic use last four weeks 
were four and five per cent, respectively, while self-reported regular use of either NSAIDs, 
opioids or paracetamol use last four weeks were 21%. The latter measure included both OTC 
or Rx use but the prevalence of opioid use, which are Rx only in Norway, was four percent. 
Overall, the different measures seemed to be relatively consistent with each other. However, 
due to the previously discussed limitations of these measures, e.g., prescription database data 
is a proxy of use, recall bias in self-reported measures, persistence definition highly dependent 
on the cut-offs chosen, and differences in exposure windows, a direct comparison is 
challenging. 
5.2.6 Validity of the chronic pain definition 
The most accurate and complete self-reported diagnosis data is recorded for concrete, chronic 
and well-known diseases, e.g., diabetes mellitus, asthma and cancers, while assessment and 
measurement of symptom-based conditions, like pain conditions is, more challenging.141(p771) 
A similar definition of chronic pain as in our study has previously been used (persistent or 
constantly recurring pain, although more than three months duration).92 A Norwegian 
validation study, comparing different measures of chronic pain, reports the highest prevalence 
for a measure that only included duration, i.e., “do you have pain lasting more than six 
months?’’.120 The authors argue that this measure captures subjects with mild pain or less and 
that a measure including at least moderate pain would exclude this group but retain those with 
persistent pain. Thus, the screening question used in our study may have captured subjects 





severe chronic pain for persistent analgesic use was explored by analysis of several 
dimensions of chronic pain severity, including chronic pain intensity. 
5.2.7 Validity of the cold pressor test 
A valid test is an unbiased test, and for experimental pain tests the question on validity is 
whether the test actually measures pain. However, pain is a subjective experience and cannot 
be measured or quantified in the same sense as for example blood pressure.17  Experimental 
pain models, although providing a way of quantifying the pain, thus provide a proxy of pain. 
As previously mentioned, pain is not exclusively bound to a stimulus, as pain may occur by 
other mechanisms.15 In experimental pain models, like the CPT, a nociceptive stimulus is 
applied in a controlled setting and the psychophysical response toward this stimulus is 
measured.17 This experimentally induced pain may therefore be different from clinical pain. 
Therefore it has been recommended that both the sensory and the affective dimensions should 
be measured, as certain analgesic interventions may affect one dimension selectively.164 
However, the CPT produces a deep, tonic, dull, aching pain of “clinical quality and 
intensity”.20 This is opposed to pain threshold tests where the clinical relevance is more 
questionable.19 The reliability, i.e., reproducibility, of the CPT is satisfactory.20 A follow-up 
of the CPT conducted in Tromsø 6 showed that the CPT has a good stability over time, i.e., a 
test-retest correlation of α = 0.82.165 It has been stated that experimental models that induce 
tonic, deep pain are needed in studies on responses to analgesic treatment,135 and that the CPT 
is ideal in the study of the effects of analgesics.20 However, there may be variability in the 
efficacy against CPT-induced pain between the different analgesic groups.20  
5.2.8 Confounding 
Confounding occurs when other factors associated with the exposure influence the outcome, 
resulting in a distortion of the association between exposure and outcome.91 An apparent but 
confounded association is thus explained partly or fully by the confounders. In DAG 
terminology, confounding refers to an open, non-causal path (“backdoor path”) between 
exposure and outcome, i.e., the confounder is a common cause (or on the path leading to or 
from the common cause) of the exposure and outcome.116(p177) If one controls for the 
confounder, either by restriction, stratification or regression, the path is closed. In the DAG 
presented in the methods section (Figure 7), open, non-causal paths between the main 
exposure, chronic pain, and the outcome, persistent analgesic use, are marked with red. Based 
on this example, the unconfounded, direct effect of chronic pain on persistent analgesic use 





psychological distress. Adjusting for the collider, self-reported health, introduces bias, i.e., a 
non-causal path is opened.  
5.2.9 Effect modification 
Effect modification, or interaction, is present when the association between exposure and 
outcome differs in different strata or levels of another variable, or when the observed joint 
effect of the exposure and the effect modifier is greater or smaller than the expected, i.e., 
synergism or antagonism, respectively.140(pp185-6) Interactions may be present on both a 
multiplicative scale and an additive scale, with the latter particularly relevant if the aim is 
intervention on a public health level. Interactions should be specified a priori based on 
(biological) plausibility. According to the principle of hierarchical backward elimination, 
interaction terms ought to be assessed before confounding. The rationale is that assessment of 
confounding involving effect modifiers becomes irrelevant in the presence of strong 
interaction.116(p170) 
I will illustrate effect modification with an example from paper II. The possible interaction 
between sex and chronic pain for the risk of persistent analgesic use was specified a priori. As 
shown in Table 5, a statistically significant interaction on the multiplicative scale between 
chronic pain and sex was found (p = .0044). The risk of persistent analgesic use was higher 
among women with chronic pain, compared to men with chronic pain. The interactions was 
also apparent on the additive scale. The interaction suggests that women with chronic pain are 
more likely than men with chronic pain to become persistent analgesic users. However, as the 
effects did not differ substantially we decided to report the overall estimate without the 
interaction term, i.e., the “average effect” of chronic pain over the sexes.140(p213) 










Women No 15.6 (13.8-17.6) Ref. 1.00 
 Yes 38.1 (34.4-42.2) 22.5 2.40 (2.03-2.85) 
Men No 15.6 (13.9-17.6) Ref. 1.00 
 Yes 26.7 (22.9-31.1) 11.1 1.65 (1.35-2.01) 
5.3 ETHICAL CONSIDERATIONS 
Autonomy, integrity and informed consent are keystones and creates the ethical foundation on 





of them, we renounce all.166(p41) Participation in a research project should therefore be 
voluntary, and the potential participant must be given necessary and adequate information 
about the study in question and its harms and benefits. The decision to participate should be 
made by a competent individual who are not subject to undue influence.167 Even after the 
decision to participate is made, the participant should be given the possibility to withdraw 
from the study at any time. Informed consent can be given orally, by voluntary actions, or as a 
signed, written consent form. Although all these options are valid from an ethical point of 
view, the written informed consent is preferable due to proof that the consent is given.167 
NorPD is a pseudonymized registry. Pseudonymization means that all personal identifiers, 
including name and PIN, is de-identified and substituted with a pseudonym, i.e., an 
identifier/key.168 Pseudonymization makes it possible to follow an individual over time or to 
link with other data sources but without knowing the individual’s identity. According to 
Norwegian legislation, informed consent is not required for registration in pseudonymized 
registers.169 Nevertheless, one may argue that mandatory registration in national health 
registries is compromising an individual’s autonomy. However, the individual will benefit 
from being registered, both directly through improved health care and indirectly through the 
benefits from research; a right to withdraw “would harm both medical care and the quality of 
medical research”,170 and could create inequalities in the population in regards to who gets 
registered or not. The latter could violate the central general ethical principle that burdens and 
benefits should be uniformly distributed across groups or individuals in a society.167 Finally, 
the informed consent may be waived in “studies using health-related registries that are 
authorized under national regulations”.167  
In the Tromsø study the participants provide written informed consent that specifically 
mentions potential linkage to NorPD and other national health registries. In long-term studies 
(e.g., 10 years) with passive follow-up it would be most appropriate to inform the participants 
and/or to seek a renewal of the informed consent. However, when the follow-up is active, like 
in repeated waves of the Tromsø Study, the participant can decide to participate or not. 





6 CONCLUDING REMARKS AND IMPLICATIONS 
The use of analgesics has increased in Norway over the last decades, a trend that is also 
observed in several other countries. In the bigger perspective this trend may reflect better 
treatment of pain and the acknowledgement of chronic pain as a disease in its own right. 
However, the increasing trend may also be influenced by marketing, introduction of new 
analgesics, availability, increasing longevity, attitudes toward analgesic use and changes in 
the prevalence of pain. The increase observed in our study seemed to be primarily in sporadic 
users of non-prescription analgesics, while the recent years’ sales statistics may suggest that 
the use of analgesics in the population is leveling out. Nevertheless, as close to sixty per cent 
of women and one third of men reported use of analgesics in a four-week period, the use of 
analgesics is extensive. Particularly worrisome was the sign of high-risk use among persons 
with contraindications or concomitant use of interacting drugs; most notably a history of 
gastrointestinal ulcers, cardiovascular disease, chronic kidney disease, and interactions 
increasing the bleeding risk or affecting renal function/blood pressure. A relatively low share 
of all users seemed to be persistent analgesic users; based on the definition and methodology 
we developed, the prevalence of persistent prescription analgesic use was four percent in 
general. Estimation of persistent drug use based on prescription registry data is 
methodologically challenging, and our method was highly dependent on the different cut-offs 
used, adding uncertainty to the model. Yet, we conclude that the majority of those reporting 
chronic pain do not use analgesics persistently. This is consistent both with an unfavorable 
adverse effects profile of persistent analgesic use, particularly for the non-steroidal anti-
inflammatory drugs and the opioids, but also with the growing body of evidence suggesting 
limited effectiveness of classical analgesic in chronic pain states. This underlies the difficulty 
and the challenge in the treatment of chronic pain, and the need for new analgesics with 
different mechanisms of action and higher efficacy.  
Our study provides epidemiological data on the association between analgesic use and pain 
sensitivity, and we have suggested hypotheses for future research. Particularly the role of 
opioid-induced hyperalgesia should be explored, also in epidemiological studies, while the 
hypothesis of paradoxically increased pain due to NSAID use should be tested. In the future, 
the use of experimental pain tests may help guide the choice of analgesics, as an addition to 





reduce the proportion of pain patients that are unnecessary exposed to potential adverse 
effects of analgesics. 
Based on this dissertation, a few clinical implications can be suggested. Prescribers need to 
take into account the patient’s comorbidity, risk of adverse effects and use of other drugs 
before prescribing an analgesic. Renal function should be measured, cardiovascular and 
gastrointestinal bleeding risk should be assessed, and drug interactions checked, particularly 
in patients on long-term NSAID treatment and in the elderly. As persistent users remain on 
treatment for a long time, the need for treatment and the risk of adverse effects should be 
continuously assessed. The pharmacist should provide information about the analgesics, both 
prescribed and OTC, in an attempt to detect potential high-risk use, e.g., drug interactions, 
concomitant use of several analgesics and/or non-prescription and prescription analgesics. At 
the population-level, the use of analgesics must be continuously monitored. Regulators need 
no assess whether the availability of the different analgesics is appropriate, based on current 
knowledge. Our results indicate high-risk use of analgesics on an overall level but future 
studies are needed to study separate analgesics, preferably stratified on non-prescription and 
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    Appendix I 
  Questionnaire 1
  Tromsø 5 
  
Light activity
(not sweating/out of breath)...
Hard physical activity
(sweating/out of breath).........
Blood pressure lowering drugs ...................
Cholesterol-lowering drugs .........................
Reading, watching TV or 
other sedentary activity? ......................................... .........
Walking, cycling or other forms of  
exercise at least 4 hours a week? .....................................
(Include walking or cycling
to work, Sunday walk/stroll,etc.)
Participation in recreational sports, heavy gardening, etc.?
(Note: duration of activity at least 4 hours a week)
Participation in hard training or sports competitions, 
regularly several times a week? ........................................
None Less than 1 1-2 3 or more
10.1 How has your physical activity in leisure time been 
during this last year?
Think of a weekly average for the year.
Time spent going to work is count as leisure time. Answer both questions.
11.3 How much interest do people show for what you do?
(Tick only once)
11.4 How many associations, sport clubs,groups, religious
        communities or similar do you take part in?  Number
(Write 0 if none)
11.5 Do you feel that you can influence what happening
in your local community where you live? (Tick only once)
12.1 Have one or more of your parents or siblings
had a heart attack (heart wound) or
angina pectoris (heart cramp)? ..........................
12.2 Tick for the relatives who have or have
had any of the illnesses: (Tick for each line)
Cerebral stroke or 
brain haemorrhage .......
Heart attack




12.3 If any relatives have diabetes, at what age did they get
diabetes (if for e.g. many siblings, consider the one who 
got it earliest in life):
11.2 How many good friends do you have? Number of friends
Count the ones you can talk confidentially with
and who can give you help when you need it.
Do not count people you live with, but do include
other relatives.
10.2 Describe exercise and physical exertion in your leisure time.
If your activity varies much e.g. between summer and winter, 
then give an average. The question refers only to the last year.
(Tick the most appropriate box)
1 2 3                 4
10. EXERCISE AND PHYSICAL ACTIVITY
11. FAMILY AND FRIENDS
12. ILLNESS IN THE FAMILY
13. USE OF MEDICINES
14. THE REST OF THE FORM IS TO
BE ANSWERED BY WOMEN ONLY
13.1 Do you use:
14.1 How old were you when you  
started menstruating? Age in years
14.2 If you no longer menstruating, how old were
you when you stopped menstruating? Age in years
14.3 Are you pregnant at the moment?
14.4 How many children have you 
        given birth to? Number of children
14.5 Do you use, or have you ever used?
(Tick once for each line)
13.2 How often have you during the last 4 weeks used
the following medicines?
(Tick once for each line)
13.3 For those medicines you have checked in points 13.1 and 























Mother's age Father's age Brother's age Sister's age Child's age
Father Brother Sister Child
None
of these
Yes, some Yes, a little No
Never 
tried




With medicines, we mean drugs purchased at pharmacies.
Supplements and vitamins are not considered here.
Painkillers non-prescription ....




Other prescription medicines ...
Oral contraceptive pills/mini pill/
contraceptive injection ................
Hormonal intrauterine device (IUD)
(not ordinary IUD)..
Estrogen (tablets or patches) .....
Estrogen (cream or suppositories)
State the name and the reason that you are taking/have taken
these (disease or symptom):











Name of the medicine: Reason for use of Up to 1 year
(one name per line) the medicine 1 year or more
If there is not enough space here, you may continue on a separate sheet that you attach
How long have you
used the medicine
Yes No Uncertain Above fertileage 






























but not now Never
14.6 If you use/have used prescription estrogen:
How long have you used it? Number of years
14.7 If you use contraceptive pills, mini pill, contraceptive 
injection, hormonal IUD or estrogen, what brand do you use?
1 2 3 4
1          2                    3        4                 5







    Appendix II 
  Questionnaire 1 









Neither good nor bad
Bad 
Very bad







3 Do you have, or have you had? Yes  No
Age first
time
A heart attack ..........................................
Angina pectoris (heart cramp) .............
Cerebral stroke/brain hemorrhage..
Atrial fibrillation ..................................... 





Psychological problems (for which you 




4 Do you have persistent or constantly recurring
pain that has lasted for 3 months or more?
Yes No
5 How often have you suffered from sleeplessness during 
 the last 12 months? 
Never, or just a few times
1-3 times a month
Approximately once a week
More that once a week
6 Below you find a list of various problems.  
Have you experienced any of this during the last week







Sudden fear without reason
Felt afraid or 
anxious ........................................
Faintness or dizziness ...........
Felt tense or
upset .............................................
Tend to blame yourself ........
Sleeping problems ..................
Depressed, sad .........................
Feeling of being useless,
worthless .....................................
Feeling that everything  
is a struggle
Feeling of hopelessness with 
regard to the future ..............
7 Have you during the last 12 months visited:
If YES; how many times?
Yes   No   No. of times
General practitioner (GP) ....................
Psychiatrist/psychologist ......................
Medical specialist outside hospital 




(homeopath, acupuncturist, foot zone therapist, 
herbal medicine practitioner, laying on hands 
practitioner,  healer, clairvoyant, etc.)
Dentist/dental service ...........................
The form will be read electronically. Please use a blue or black pen 
You can not use comas, use upper-case letters.
2007 – 2008 Confidential
9 Have you undergone any surgery during the last 3 years?
Yes No
8 Have you during the last 12 months been to  
a hospital? Yes  No  No. of times
Admitted to a hospital ...........................
Had consultation in a hospital without admission;
At psychiatric out-patient clinic
At another out-patient clinic .....
USE OF HEALTH SERVICES
HEALTH AND DISEASES





19 What is your main activity? (Tick once)
Full time work Housekeeping
Part time work Retired/benefit recipient
Unemployed Student/military service
10 Do you currently use, or have you used some of 






Blood pressure lowering drugs 
Cholesterol lowering drugs ...





Tablets for diabetes ................
The drugs for hypothyroidism 
Thyroxine/levaxin ....................
11 How often have you during the last 4 weeks used
the following medicines? (Tick once for each line)
Not used 















12 State the name of all medicines -both those on 
prescription and non-prescription drugs- you 
have used regularly during the last 4 weeks.  
Do not include vitamins, minerals, herbs, natural  
remedies, other nutritional supplements, etc. 
When attending you will be asked whether you 
have used antibiotics or painkillers the last 24 
hours. If you have, you will be asked to provide the 
name of the drug, strength, dose and time of use. 
13 Who do you live with? (Tick for each question 
and give the number)
Yes No Number
Spouse/partner ....................................
Other people older than 18 years..
People younger than 18 years ........
14 Tick for the relatives who have or have had
Parents Children Siblings
A heart attack ...................................
A heart attack before age of 60 









15 Do you have enough friends who can give you 
help when you need it?  
Yes No
16
Do you have enough friends whom you can talk 
confidentially with? 
Yes No
17 How often do you normally take part in 
organised gatherings, e.g. sport clubs, political 
meetings, religious or other associations? 
Never, or just a few times a year
1-2 times a month
Approximately once a week
More than once a week
WORK, SOCIAL SECURITY AND INCOME 
18 What is the highest level of education you have 
completed? (Tick once)
Primary/secondary school, modern secondary school
Technical school, vocational school, 1-2 years  
senior high school
High school diploma
College/university less than 4 years
College/university 4 years or more
FAMILY AND FRIENDS
If there is not enough space for all medicines, continue on a 
separate sheet.
USE OF MEDICINES
25 How often do you exercise?  (With exercise we mean
for example walking, skiing, swimming or 
training/sports) 
Never
Less than once a week
Once a week
2-3 times a week
Approximately every day
36 How many years in all have you smoked daily? 
Number of 
years
35 How old were you when you began daily smoking?
Age in years
22 Do you work outdoor at least 25% of the time, or  
in cold buildings (e.g. storehouse/industry  
buildings)?
Yes No
23 If you have paid or unpaid work, which statement  
describes your work best?
Mostly sedentary work
(e.g. office work, mounting)
Work that requires a lot of walking
(e.g. shop assistant, light industrial work, teaching)
Work that requires a lot of walking and lifting
(e.g. postman, nursing, construction)
Heavy manual labour
24
Reading, watching TV, or other sedentary 
activity.
Walking, cycling, or other forms of exercise
at least 4 hours a week (include walking or  
cycling to work, Sunday-walk/stroll, etc.)
Participation in recreational sports, heavy gardening, 
etc. (note:duration of activity at least 4 hours a week)
Participation in hard training or sports 
competitions, regularly several times a week.
26 How hard do you exercise on average?
Easy- do not become short-winded or sweaty
You become short-winded and sweaty
Hard- you become exhausted
29 How many units of alcohol(a beer, a glass of wine or 
a drink) do you usually drink when you drink alcohol?
1-2 5-6 10 or more
3-4 7-9






27 For how long time do you exercise every time on average?
Less than 15 minutes 30-60 minutes
15-29 minutes More than 1 hour
30 How often do you drink 6 units of alcohol or more  
in one occasion?
Never
Less frequently than monthly
Monthly
Weekly
Daily or almost daily
28 How often do you drink alcohol?
Never
Monthly or less frequently
2-4 times a month
2-3 times a week
4 or more times a week
21 What was the household's total taxable income last
year? Include income from work, pensions, benefits
and similar
Less than 125 000 NOK 401 000-550 000 NOK
125 000-200 000 NOK 551 000-700 000 NOK
201 000-300 000 NOK 701 000 -850 000 NOK 
301 000-400 000 NOK More than 850 000 NOK
34 If you currently smoke, or have smoked previously: 








31 Do you smoke sometimes, but not daily?
Yes No




Transition benefit for single parents
Social welfare benefits
37 Do you use or have you used snuff or chewing tobacco?
No, never Yes, sometimes
Yes, previously Yes, daily
PHYSICAL ACTIVITY
ALCOHOL AND TOBACCO
Old-age, early retirement or survivor pension
Sickness benefit (on sick leave)
Rehabilitation benefit
Describe your exercise and physical exertion in 
leisure time. If your activity varies much, e.g.  
between summer and winter, then give an 
average. The question refers only to the last 
year. (Tick the most appropriate box)
48 If you have given birth, fill in for each child: 
birth year, birth weight and months of  
breastfeeding (Fill in the best you can)
Child Birth year Birth weight in grams








39 How many units of fruit or vegetables do you eat
on average per day? (units means for example
a fruit, a cup of juice, potatoes, vegetables)
Number of units
38 Do you usually eat breakfast every day?
40 How many times a week do you eat warm dinner? 
Number
42 How much do you usually drink the following?  











44 How often do you usually eat cod liver and roe? 
(i.e. “mølje”)
Rarely/never 1-3 times/year 4-6 times/year
























4 or more 
glasses 
/day
Do you currently use any prescribed drug  
influencing the menstruation? 
45 Do you use the following nutritional supplements? 
Daily  Sometimes  No
Cod liver oil or fish oil capsules .........
Omega 3 capsules (fish oil, seal oil) ........
Calcium tablets ...........................................
47 How many children have you given birth to?
Number
49 Have you during pregnancy had high blood  
pressure?  
Yes No
52 If yes, during which pregnancy?
The first Second or later
53 Were any of your children delivered prematurely  
(a month or more before the due date) because  
of preeclampsia?
Yes No
55 How old were you when you started  
menstruating? 
Age
51 Have you during pregnancy had proteinuria?  
Yes No
50 If yes, during which pregnancy?
The first Second or later
54 If yes, which child?
1st child 2nd child 3rd child 4th child 5th child 6th child
43 How many cups of coffee and tea do you drink 
daily? (Put 0 for the types you do not drink daily)
Number of cups
Filtered coffee ...............................................
Boiled coffee (coarsely ground coffee for brewing)
Other types of coffee ..................................
Tea ......................................................................
56
Oral contraceptives, hormonal 
intrautrine or similar ............................ Yes No
Hormone treatment for  
menopausal problems ........................... Yes No
46 Are you pregnant at the moment? 
Yes No Uncertain
When attending you will get supplementary  
questions about menstruation and any use  
of hormones. Write down on a sheet of paper  
the names of all the hormones you have used  
and bring it with you. You will also be asked  
whether your menstruation have ceased and  
possibly when and why. 
 
41 How often do you usually eat these foods? 
(Tick once for each line)
Potatoes ..............................
Pasta/rice ..........................
Meat (not processed) ............
Processed meat
(sausages, hamburger, etc.) ....
Fruits, vegetables, berries
Lean fish .............................
Fatty fish  ..........................
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1.6 To allow you to show us how good or bad 
your state of health is we have made a 
scale (almost like a thermometer) where 
the best state of health you can imagine is 
marked 100 and the worst 0. We ask you to 
show your state of health by drawing a line 
from the box below to the point on the 
scale that best fits your state of health.   















1. DESCRIPTION OF YOUR HEALTH STATUS
Mark the statement that best fits your 
state of health today by ticking once in 
one of the boxes under each of the five 
groups below: 
1.03 Usual activities (e.g. work, study, housework,
family or leisure activities)
I have no problems with performing my
usual activities 
I have some problems with performing my
usual activities 
I am unable to perform my usual 
activities 
1.04 Pain and discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
1.01 Mobility 
I have no problems in walking 
about 
I have little problems in walking about
I am confined to bed
1.02 Self-care 
I have no problems with self-care
I have some problems washing or 
dressing myself 
I am unable to wash or dress myself
1.05 Anxiety and depression
I am not anxious or depressed
I am moderately anxious or depressed




4.01 Have you during the last month 
experienced any illness or injury?
Yes No
4. ILLNESS AND WORRIES
4.03Do you become breathless in the following 
situations? (tick once for each question)
Yes  NoWhen you walk rapidly on level 
ground or up a moderate slope .............
When you walk calmly on level 
ground ...................................................................
While you are washing or dressing ......
At rest ....................................................................
4.04 Do you cough about daily for some 
periods of the year?
Yes No
If YES: Is the cough usually productive?
Yes No
Have you had this kind of cough for as long 
as 3 months in each of the last two years? 
Yes No
4.02 Have you noticed sudden changes in your 
pulse or heart rythm in the last year? 
Yes No
4.09 Below, please answer a few questions
about your memory: (tick once for each 
question)
Yes  No
Do you think that your memory
has declined? ....................................................
Do you often forget where you 
have placed your things? ..........................
Do you have difficulties finding 
common words in a conversation? ......
Have you problems performing 
daily tasks you used to master? ............
Have you been examined for 
memory problems? ........................................
If YES: have you during the same period?
(Tick once for each line)
Yes  No
Been to a general practitioner ..............
Been to a medical specialist ...................
Been to emergency department ...........
Been admitted to a hospital ....................
Been to an alternative  practitioner
(chiropractor, homeopath or similar) .............
If YES to at least one of the first four questions
above: Is this a problem in your daily life?
Yes No
4.05How often do you suffer from sleeplessness? 
(tick once)
Never, or just a few times a year
1-3 times a month
Approximately once a week
More than once a week
If you suffer from sleeplessness monthly or 
more often, what time of the year does it 





4.06 Have you had difficulty sleeping during 
the past couple of weeks? 
Not at all
No more than usual
Rather more than usual
Much more than usual
4.07 Have you during the last two weeks felt 
unhappy and depressed?
Not at all
No more than usual
Rather more than usual
Much more than usual
4.08 Have you during the last two weeks felt
unable to cope with your difficulties?
Not at all
No more than usual
Rather more than usual
Much more than usual
7
4.17 If you have had abdominal pain or 
discomfort during the last year:
Yes  No
Was it located in your upper stomach?.
Were you bothered as often as once a
week or more during the last 3 months?... 
Became better after bowel movement?...
Are the symptoms related to more 
frequent or rare bowel movements  
than normally? ....................................................
Are the symptoms related to more
loose or hard stool than normally?............. 
Do the symptoms appear after a meal? ....
4.15Have you ever experienced infertility 
for more than 1 year?
Yes No
If Yes: was it due to: Do not 
knowYes No
A condition concerning you?......
A condition concerning your 
partner?.........................................................
4.14 Do you have or have you ever had some 
of the following:




4.19 For women: Have you ever had a 
miscarriage?
Yes No Do not know
If Yes: number of times .........................
4.16 To which degree have you had the following 
complaints during the last 12 months?









4.20For men: Have your partner ever had 
a miscarriage?
Yes No Do not know
If Yes: number of times .........................
4.22Have you been diagnosed with 
Dermatitis Herpetiformis (DH)? 
Yes No Do not know
4.21 Is your diet gluten-free?
Yes No Do not know
4.11 Have you suffered from pain and/or 
stiffness in muscles or joints during 
the last 4 weeks  
No A little   A lot
Neck, shoulder .......................
Arms, hands .............................
Upper part of the back .....
The lumbar region ...............
Hips, leg, feet ........................
Other places ............................
4.10 Have you during the last last year suffered 
from pain and/or stiffness in muscles or 
joints in your neck/shoulders lasting for 
at least 3 consecutive months?
(tick once for each line)
No A little   A lot
Neck, shoulder......................
Arms, hands............................




4.12 Have you ever had: Age 




4.18 Have you ever had: Age
last timeYes  No
Stomach ulcer ......................
Duodenal ulcer ....................




4.27 What kind of headache are you 
suffering from?
Migraine Other headache
4.28 How many days per month do you 
suffer from headache? 
Less than one day
1-6 days 
7-14 days
More than 14 days
4.26 Have you been suffering from 
headache the last year?
Yes No
If No: go to section 5, food habits
4.30 What is the intensity of your headache? 
Mild (do not hinder normal activity) 
Moderate (decrease normal activity) 
Strong (block normal activity) 
4.31 What is the duration of the headache  
usually?
Less than 4 hours
4 hours – 1 day
1-3 days
More than 3 days
4.29 Is the headache usually:
(tick one for each line)
Yes   No
Pounding/pulsatory pain ..............
Pressing/tightening pain ............. 
Unilateral pain (right or left) ........ 
4.33 Before or during the headache, do you 
have a transient: Yes  No
Visual disturbances? (flickering,  
blurred vision, flashes of light)....................
Unilateral numbness in your face 
or hand? ...........................................................
Deterioration by moderate physical 
Activity? ...........................................................
 
Nausea and/or vomiting? ......................
4.34 Describe how many days you have been 
away from work or school during the 
last month due to headache?
Number of days ............................................
4.32 If you suffer from headache, when during






4.23 Have you been diagnosed with coeliac 
disease, based on a biopsy from your 
intestine taken in an endoscopy 
examination?
Yes No Do not know
4.24 Do you have your natural teeth?
Yes No
4.25 How many amalgam tooth fillings do 
you have/have you had?
0 1-5 6-10 10+
19
13.01 How long have you had this pain?
Number of years months










13.02 How often do you have this pain?
Every day Once a month or more
Once a week or more Less than once a month
13.05 Which kind of treatment have you received for the pain? (Tick for all types of pain 
treatments you have received) 
No treatment Psycho-educative/relaxation training/
psychotherapy
Analgesic medications Acupuncture 
Physiotherapy/chiropractic treatment Complimentary medicine 
(homeopathy, healing, aromatherapy, etc. Treatment at a pain clinic
Surgery Another treatment
You answered in the first questionnaire that you have protracted or constantly recurrent 
pain that has lasted for 3 months or more. Here, we ask you to describe the pain a little closer.
13. FOLLOW-UP QUESTIONS ON PAIN
13.04 What do you believe is the cause of the pain? (Tick for all known causes) 
Accident /acute injury Fibromyalgia  
Long-term stress Angina pectoris 
Surgical intervention/operation Poor blood circulation 
Herniated disk (prolapse) /lumbago Cancer 
Whiplash Nerve damage/neuropathy 
Migraine/headache Infection 
Osteoarthritis Herpes zoster 
Rheumatoid arthritis Another cause (describe below)
Bechterews syndrome Don't know
Describe the other cause:
..........................................................................................................................................................................................................
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13.06 On a scale of 0 to 10, where 0 corresponds to no pain and 10 corresponds to the worst 




to sleepTo what degree does the pain 
interfere with your sleep?  ............................................
0 1 2 3 4 5 6 7 8 9 10
Can not do
anythingTo what degree does the pain 
interfere with performing common
activities at home and at work?  .............................
0 1 2 3 4 5 6 7 8 9 10
How strong is the pain when it is in 
its strongest intense? .........................................................





painHow strong would you say that the 
pain usually is? ....................................................................
0 1 2 3 4 5 6 7 8 9 10
No
pain 
No 
effect
Worst 
imaginable 
pain
